Team 5: Atherothrombotic Disease in Heart and Brain

Team leaders: P Gabriel STEG (PU-PH UPC) & Grégory DUCROCQ (PU-PH UPC)

T1

TEAM 1

T2

TEAM 2

T3

TEAM 3

T4

TEAM 4

T5Coul

TEAM 5

T6

TEAM 6

Hub innov

Innovation & Industrial partnerships Hub

Secretariat

Secretary

ServicesCommuns

Common services

Project Outlines

The Atherothrombotic disease in heart and brain team (Team 5, P.G. Steg) focuses on clinical epidemiology of CAD (P. Gabriel Steg) and stroke (P. Amarenco), via the design, conduct and analysis of large-scale observational registries and of randomized clinical trials. The team received French government funding for an integrated research program on innovations in atherothrombosis science (RHU IVASC) which involves ongoing epidemiologic studies and interventional studies to establish the relationship(s) between chronic periodontitis, sleep disordered breathing, and atherothrombosis. The TIA.org registry established the benefit of rapid management of transient ischaemic attacks through specialized centers worldwide, initially and at 5-year follow-up.

Recent trials have studied the impact of lipid lowering interventions after acute coronary syndromes (using alirocumab, a PCSK9 inhibitor, in the ODYSSEY OUTCOMES trial) or after ischaemic stroke in patients with atherothrombosis (comparing two target LDL cholesterol levels, in the TST trial which established the clinical benefit of targeting LDL to <70 mg/dL rather than 100 mg/dL). A large-scale trial, THEMIS (the largest randomized trial in diabetes) established the value of dual antiplatelet therapy with ticagrelor and aspirin in patients with stable CAD and diabetes, particularly if they have a prior history of percutaneous coronary intervention.

The research program will be developed on 3 different and synergistic aspects:

1/ Registry-based randomized clinical trials and novel trial designs

2/ Deep learning and cardiology

3/ Evaluation of novel risk factors for atherothrombosis.

Staff of the team

Family name
First name
Position
Tel
Email
ORCID
ABERGELHélèneIR01.57.27.53.57helene.abergel@aphp.fr
ABTANJérémieDoctorantjeremie.abtan@aphp.frhttps://orcid.org/0000-0001-8968-6624
ALGALARRONDOVincentMCUPHvincent.algalarrondo@gmail.com
AMARENCOPierrePUPH01.40.25.87.25pierre.amarenco@aphp.frhttps://orcid.org/0000-0002-3842-1236
BADJIHichem AhmedDoctorant01.40.25.75.29hichem.badji@inserm.fr
BERARDLaurencePHlaurence.berard@aphp.fr
BOUFFARDCatherinePHcatherine.bouffard@aphp.fr
DROUETElodieAHUelodie.drouet@aphp.fr
DUCROCQGregoryPUPH01.40.25.77.31gregory.ducrocq@aphp.frhttps://orcid.org/0000-0003-4069-1128
ELBEZYedidAutre_Chyedid.elbez@aphp.frhttps://orcid.org/0000-0002-1883-8632
FARNOUDRezaIR01.40.25.83.64reza.farnoud@aphp.frhttps://orcid.org/0000-0001-5097-2041
FELDMANLaurentPUPHlaurent.feldman@aphp.frhttps://orcid.org/0000-0003-2626-703X
FLAMANDMartinPUPHmartin.flamant@aphp.fr
FUENTESAxelleAHUaxelle.fuentes@gmail.com
GAUTIERAlexandreCCAgautier.alx@gmail.com
GEDIKSinemStag M2sinem.gedik@etu.u-paris.fr
GUIDOUXCélinePHceline.guidoux@aphp.fr
HOBEANUCristinaPHcristina.hobeanu@aphp.fr
LAVALLEEPhilippaMCUPH01.40.25.70.33philippa.lavallee@aphp.frhttps://orcid.org/0000-0002-8148-7679
LIZhipengDoctorantlzpeng1206@gmail.com
LONGROISDanPUPH01.40.25.74.27dan.longrois@aphp.frhttps://orcid.org/0000-0001-5864-8975
MERHEBGaelleDoctorantgaellemerheb@hotmail.com
MESEGUER GANCEDOElenaPH01.40.25.74.90elena.meseguer@aphp.frhttps://orcid.org/0000-0002-7184-2614
MESNIERJulesPHmesnier.jules@gmail.comhttps://orcid.org/0000-0002-2131-6763
NORELXavierIR01.40.25.75.29xnorel@hotmail.comhttps://orcid.org/0000-0003-0734-3359
PACOSandraAHUsandra.paco@aphp.fr
ROGERGuillaumeAutre_ChVIDE
ROUSSEAUAlexandraCDDBVIDE
SIMONTabassomePUPHtabassome.simon@sat.aphp.frhttps://orcid.org/0000-0002-4550-0450
SPIELERJean-FrançoisMCF01.40.25.87.28jean-francois.spieler@aphp.fr
STEGPhilippe GabrielPUPH01.40.25.73.25gabriel.steg@aphp.frhttps://orcid.org/0000-0001-6896-2941
TOUBOULPierre-JeanPUPH01.40.25.87.25pjtw@noos.frhttps://orcid.org/0000-0002-8872-9917
VIDAL-PETIOTEmmanuellePUPHemmanuelle.vidal-petiot@aphp.fr
ZENJEBILSandraCCAVIDE

Publications

2025

2024

1.
Wiernik E, Renuy A, Kab S, Steg PG, Goldberg M, Zins M, Caligiuri G, Bouchard P, Carra MC. 2024. Prevalence of self‐reported severe periodontitis: Data from the population‐based CONSTANCES cohort. Journal of Clinical Periodontology 51:884–894.
1.
Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, Bellows BK, Derington CG, Philip S, Steg G, Miller M, Brinton EA, Jacobson TA, Tardif J, Ballantyne CM, Kolm P. 2024. Cost‐Effectiveness of Icosapent Ethyl in REDUCE‐IT USA: Results From Patients Randomized in the United States. Journal of the American Heart Association 13:e032413.
1.
Steg PG. 2024. Routine Beta-Blockers in Secondary Prevention — On Injured Reserve. New England Journal of Medicine 390:1434–1436.
1.
Simon T, Herbert BM, Brooks MM, Goodman SG, Alexander JH, Steg PG, Lopes RD, Ghafghazi S, Bouleti C, Cooper HA, McCamant EL, Bainey KR, Aronow HD, Abbott JD, Alsweiler C, Bertolet M, Fergusson DA, Goldsweig AM, Hébert PC, Carson JL, on behalf of the MTI. 2024. Restrictive or Liberal Transfusion Strategy in Patients With Acute Myocardial Infarction and Anemia: 6-Month Mortality in the MINT Trial. Circulation 150:1064–1066.
1.
Sherratt SCR, Mason RP, Libby P, Steg PG, Bhatt DL. 2024. Do patients benefit from omega-3 fatty acids? Cardiovascular Research 119:2884–2901.
1.
Sayah N, Skalidis I, Mesnier J, Neylon A, Akodad M, Asgar A. 2024. Cerebral Embolic Protection Devices: Are There Any Indications in Transcatheter Aortic Valve Replacement? Journal of Clinical Medicine 13:5471.
1.
Roger G, Ducrocq G, Mesnier J, Sayah N, Abtan J, Ferrari R, Ford I, Fox KM, Tardif J-C, Tendera M, Feldman LJ, Elbez Y, Steg PG, Investigators C, Steg PG, Ferrari R, Ford I, Fox KM, Tardif JC, Tendera M, Sokn FJ, Reid C, Lang I, Van Den Branden F, César LM, Luqman N, Goudev A, Dorian P, Hu D, Widimsky P, Hassager C, Danchin N, Kääb S, Vardas P, Sulaiman KJ, Al Mahmeed W, Al Suwaidi J, Al Rashdan I, Abdulkader F, Merkely B, Kaul U, Daly K, Tavazzi L, Ferrari R, Jang Y, Erglis A, Laucevičius A, Jamaluddin AN, Gamba MA, Tulevski II, Stępińska J, Morais J, Macarie C, Oganov R, Shalnova S, Al-Zaibag M, Hou MK, Kamensky AG, Fras Z, Kanič V, Naidoo DP, Zamorano JL, Rickli H, Jaussi A, Sriratanasathavorn AC, Kalra P, Lutai M, Parkhomenko O, Nguyen LV, Henry R, Ahuad Guerrero A, Basara M, Belcastro F, Bertarini JA, Cazenave C, Dreycopp H, Egido J, Estrella J, Garofalo D, Giordano J, Lagioia H, Lago N, La Greca R, Lema L, Lopez Cabanillas N, Luquez H, Miller C, Prada E, Rodenas P, Schena RG, Suarez G, Tomatti A, Colquhoun DM, Conradie A, Cox S, Cross D, Fathi R, Fitzgerald B, Hamilton-Craig I, Holt G, others. 2024. Chronic coronary syndromes without standard modifiable cardiovascular risk factors and outcomes: the CLARIFY registry. European Heart Journal 45:2396–2406.
1.
Puymirat E, Cayla G, Simon T, Steg PG, Montalescot G, Durand-Zaleski I, Ngaleu Siaha F, Gallet R, Khalife K, Morelle J-F, Motreff P, Lemesle G, Dillinger J-G, Lhermusier T, Silvain J, Roule V, Labèque J-N, Rangé G, Ducrocq G, Cottin Y, Blanchard D, Charles Nelson A, Djadi-Prat J, Chatellier G, Danchin N, for the F-MISI. 2024. Three-Year Outcomes With Fractional Flow Reserve–Guided or Angiography-Guided Multivessel Percutaneous Coronary Intervention for Myocardial Infarction. Circulation: Cardiovascular Interventions 17.
1.
Poorthuis MHF, Hageman SHJ, Fiolet ATL, Kappelle LJ, Bots ML, Steg PG, Visseren FLJ, Bhatt DL, De Borst GJ. 2024. Prediction of Severe Baseline Asymptomatic Carotid Stenosis and Subsequent Risk of Stroke and Cardiovascular Disease. Stroke 55:2632–2640.
1.
Mesnier J, Cruz-González I, Guedeney P, Arzamendi D, Freixa X, Nombela-Franco L, Peral V, Caneiro-Queija B, Mangieri A, Trejo-Velasco B, Asmarats L, Cepas-Guillén P, Salinas P, Siquier-Padilla J, Estevez-Loureiro R, Laricchia A, O’Hara G, Montalescot G, Rodés-Cabau J. 2024. Early Nonprocedural Bleeding After Left Atrial Appendage Occlusion. JACC: Cardiovascular Interventions 17:1765–1776.
1.
Lemesle G, Lamblin N, Schurtz G, Labreuche J, Duhamel A, Verdier B, Steg PG, Bauters C. 2024. Comparison of Incidence and Prognostic Impact of Ischemic, Major Bleeding and Heart Failure Events in Patients With Chronic Coronary Syndrome: Insights From the CORONOR Registry. Circulation 149:1708–1716.
1.
Grave C, Bonaldi C, Carcaillon-Bentata L, Gabet A, Halimi J-M, Tzourio C, Béjot Y, Torres MJ, Steg PG, Durand Zaleski I, Blacher J, Olié V. 2024. Burden of Cardio-Cerebrovascular and Renal Diseases Attributable to Systolic Hypertension in France in 2021. Hypertension HYPERTENSIONAHA.124.23760.
1.
Gautier A, Picard F, Ducrocq G, Elbez Y, Fox KM, Ferrari R, Ford I, Tardif J-C, Tendera M, Steg PG, investigators C, Guerrero AA, Basara M, Belcastro F, Bertarini JA, Cazenave C, Dreycopp H, Egido J, Estrella J, Garofalo D, Giordano J, Lagioia H, Lago N, Greca RL, Lema L, Cabanillas NL, Luquez H, Miller C, Prada E, Rodenas P, Schena RG, Suarez G, Tomatti A, Colquhoun DM, Conradie A, Cox S, Cross D, Fathi R, Fitzgerald B, Hamilton-Craig I, Holt G, Jayasinghe SR, Mai N, Moolman J, Motyer RA, Phillips K, Rafter A, Rahman A, Rainbird A, Scalia G, Taylor A, West P, Alford K, Amor R, Astridge P, Bastian B, Bates F, Doohan MM, Du Plooy J, Ford JC, Kanagaratnam L, Khoury V, Parkin R, Rogers J, Sceats G, Waldman A, Wang D, Wright S, Ardill J, Aylward P, Beltrame JF, Bradley J, Heddle W, Joseph M, Rajendran S, Varughese S, Brice E, Hockings B, Janssen J, Kozlowski A, O’Shea J, Tan J, Playford DA, Woollard K, Ajani A, Barron G, Better N, Carruthers T, Chan B, Chan R, Cotroneo J, Counsell JT, Eccleston DS, Forge BHR, Hamer A, Horrigan M, Jelinek VMJ, Lew R, O’Donnell D, Panetta F, others. 2024. New-onset atrial fibrillation and chronic coronary syndrome in the CLARIFY registry. European Heart Journal 45:366–375.
1.
El Bèze N, Steg PG. 2024. Heart failure and revascularization: which method to choose and should we even do it? European Heart Journal ehae715.
1.
Dinu M, Sofi F, Lotti S, Colombini B, Mattioli AV, Catapano AL, Casula M, Baragetti A, Wong ND, Steg PG, Ambrosio G. 2024. Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis. European Journal of Preventive Cardiology zwae184.
1.
Burger PM, Bhatt DL, Dorresteijn JAN, Koudstaal S, Mosterd A, Martens FMAC, Steg PG, Visseren FLJ, for the R-ITI, Ladner J, Kakish L, Kakish A, Little AL, Gerber J, Hinchion NJ, Guarino J, Raychok D, Budzinski S, Kelley-Garvin K, Beckord A, Schlinder J, Schwartzbard A, Cobos S, Freeman D, Abisalih D, McCann D, Guy K, Chase J, Samuelson S, Cassidy M, Tardif M, Smith J, Sprout B, Riedeman N, Goza J, Johnson L, Kraske C, Hastings S, Dutka C, Smith S, McCabe T, Maloney K, Alfieri P, Hosemane V, Syravanh C, Pau C, Limcoiloc A, Carreira T, Kurosawa TS, Kurosawa TS, Krumian R, Preston K, Nashed A, Schneidman-Fernandez D, Patterson J, Tsakonas J, Esaki J, Sprafka L, Patel P, Mitchell B, Ross EM, Miller D, Prashad A, Feyler KM, Juarbe N, Herrera S, Keiran SM, Whitehead B, Asher W, Hobbs C, Elie A, Brooks J, Zaleski AL, Foxen B, Lapke B, Wright P, Pavol B, Carangi G, Turner M, Ellison HS, Sanders KW, Delamar RS, Wilson VL, Harvel SM, Cartledge AM, Bailey KR, Mahon K, Schuchard T, Humbert J, Hanson MC, Cecil MP, Abraham JS, Benedict L, Slayton C, Burnett CS, Ono-Lim RW, Budzinski S, Khan SA, Goss S, Techmanski T, others. 2024. Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT. European Heart Journal - Cardiovascular Pharmacotherapy 10:488–499.
1.
Boden WE, De Caterina R, Kaski JC, Bairey Merz N, Berry C, Marzilli M, Pepine CJ, Barbato E, Stefanini G, Prescott E, Steg PG, Bhatt DL, Hill JA, Crea F. 2024. Myocardial ischaemic syndromes: a new nomenclature to harmonize evolving international clinical practice guidelines. European Heart Journal 45:3701–3706.
1.
Balagny P, Vidal-Petiot E, Kab S, Frija J, Steg PG, Goldberg M, Zins M, d’Ortho M-P, Wiernik E. 2024. Association of Snoring and Daytime Sleepiness With Subsequent Incident Hypertension: A Population-Based Cohort Study. Hypertension 81:2286–2297.

2023

1.
Vidal-Petiot E, Elbez Y, Mesnier J, Ducrocq G, Ford I, Tendera M, Ferrari R, Tardif J-C, Fox KM, Steg PG. 2023. Optimal or standard control of systolic and diastolic blood pressure across risk factor categories in patients with chronic coronary syndromes. European Journal of Preventive Cardiology 30:935–947.
1.
Steg PG, Kikoïne J. 2023. Do We Need Ischemia Testing to Monitor Asymptomatic Patients With Chronic Coronary Syndromes? Circulation 147:5–7.
1.
Salaun E, Bernier M, Paradis J-M, Champagne J, Silva Conde I, Beaudoin J, O’Connor K, Dognin N, Alperi A, Mesnier J, Panagides V, Lemyre M, Rodes-Cabau J, O’Hara G. 2023. Watchman 2.5TM versus Watchman FLXTM device in atypical left atrial anatomies: old fashion never dies. Acta Cardiologica 78:372–376.
1.
Rodés-Cabau J, Mesnier J. 2023. Is Left Atrial Appendage Occlusion Safe and Effective in Octogenarians? JACC: Clinical Electrophysiology 9:677–679.
1.
Popovic B, Ducrocq G, Elbez Y, Bode C, Mehta SR, Pollack CV, Sabate M, Rao SV, Parkhomenko A, Feldman LJ, Sayah N, Sabatine MS, Steg PG. 2023. Clinical Significance of Culprit Vessel Occlusion in Patients With Non–ST-Elevation Myocardial Infarction Who Underwent Percutaneous Coronary Intervention. The American Journal of Cardiology 188:95–101.
1.
Parker WAE, Angiolillo DJ, Rollini F, Franchi F, Bonaca MP, Bhatt DL, Steg PG, Orme RC, Thomas MR, Judge HM, Sabatine MS, Storey RF. 2023. Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes. Vascular Pharmacology 149:107145.
1.
Olshansky B, Bhatt DL, Miller M, Steg PG, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT, Juliano RA, Jiao L, Kowey PR, Reiffel JA, Tardif J, Ballantyne CM, Chung MK, the RI. 2023. Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT. Journal of the American Heart Association 12:e026756.
1.
Nuche J, Masso van-Roessel A, Nault I, Paradis J-M, De Larochellière R, Mesnier J, Champagne J, Mohammadi S, Philippon F, Rodés-Cabau J. 2023. Temporary active fixation lead pacemaker in transcatheter aortic valve replacement patients with right bundle branch block. Heart Rhythm 20:309–310.
1.
Mimouni M, Bulsei J, Darlington M, Estellat C, Rouzet F, Hyafil F, Durand-Zaleski I, the RTG, Chequer R, Ducrocq G, Alfaiate T, Regaieg H, Abtan J, Leygnac S, Milliner M, Burg S, Azzouna RB, Potier L, Laouénan C, Quintin C, Roussel R, Steg G, Le Guludec D, Sorbets E, Imbert L, Marie P-Y, Hartemann A, Montalescot G. 2023. Cost-effectiveness of 82-Rubidium PET myocardial perfusion imaging for the diagnosis of myocardial ischemia depending on the prevalence of coronary artery disease. EJNMMI Research 13:9.
1.
Mesnier J, Ternacle J, Cheema AN, Campelo-Parada F, Urena M, Veiga-Fernandez G, Nombela-Franco L, Munoz-Garcia AJ, Vilalta V, Regueiro A, Del Val D, Asmarats L, Del Trigo M, Serra V, Bonnet G, Jonveaux M, Rezaei E, Matta A, Himbert D, De La Torre Hernandez JM, Tirado-Conte G, Fernandez-Nofrerias E, Vidal P, Alfonso F, Gutierrez-Alonso L, Oteo JF, Belahnech Y, Mohammadi S, Philippon F, Modine T, Rodés-Cabau J. 2023. Cardiac Death After Transcatheter Aortic Valve Replacement With Contemporary Devices. JACC: Cardiovascular Interventions 16:2277–2290.
1.
Mesnier J, Simard T, Jung RG, Lehenbauer KR, Piayda K, Pracon R, Jackson GG, Flores-Umanzor E, Faroux L, Korsholm K, Chun JKR, Chen S, Maarse M, Montrella K, Chaker Z, Spoon JN, Pastormerlo LE, Meincke F, Sawant AC, Moldovan CM, Qintar M, Aktas MK, Branca L, Radinovic A, Ram P, El-Zein RS, Flautt T, Ding WY, Sayegh B, Benito-González T, Lee O-H, Badejoko SO, Paitazoglou C, Karim N, Zaghloul AM, Agarwal H, Kaplan RM, Alli O, Ahmed A, Suradi HS, Knight BP, Alla VM, Panaich SS, Wong T, Bergmann MW, Chothia R, Kim J-S, Pérez De Prado A, Bazaz R, Gupta D, Valderrábano M, Sanchez CE, El Chami MF, Mazzone P, Adamo M, Ling F, Wang DD, O’Neill W, Wojakowski W, Pershad A, Berti S, Spoon DB, Kawsara A, Jabbour G, Boersma LVA, Schmidt B, Nielsen-Kudsk JE, Freixa X, Ellis CR, Fauchier L, Demkow M, Sievert H, Main ML, Hibbert B, Holmes DR, Alkhouli M, Rodés-Cabau J. 2023. Persistent and Recurrent Device-Related Thrombus After Left Atrial Appendage Closure. JACC: Cardiovascular Interventions 16:2722–2732.
1.
Miller M, Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Jiao L, Tardif J-C, Ballantyne CM, Budoff M, Mason RP. 2023. Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking. European Heart Journal - Cardiovascular Pharmacotherapy 9:129–137.
1.
Mesnier J, Cepas-Guillén P, Freixa X, Flores-Umanzor E, Hoang Trinh K, O’Hara G, Rodés-Cabau J. 2023. Antithrombotic Management After Left Atrial Appendage Closure: Current Evidence and Future Perspectives. Circulation: Cardiovascular Interventions 16.
1.
Marquis‐Gravel G, Boivin‐Proulx L, Huang Z, Zelenkofske SL, Lincoff AM, Mehran R, Steg PG, Bode C, Alexander JH, Povsic TJ. 2023. Femoral Vascular Closure Devices and Bleeding, Hemostasis, and Ambulation Following Percutaneous Coronary Intervention. Journal of the American Heart Association 12:e025666.
1.
Lamy A, Eikelboom J, Tong W, Yuan F, Bangdiwala SI, Bosch J, Connolly S, Lonn E, Dagenais GR, Branch KRH, Wang W-J, Bhatt DL, Probstfield J, Ertl G, Störk S, Steg PG, Aboyans V, Durand-Zaleski I, Ryden L, Yusuf S. 2023. The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial. European Heart Journal - Quality of Care and Clinical Outcomes 9:502–510.
1.
Hochman JS, Anthopolos R, Reynolds HR, Bangalore S, Xu Y, O’Brien SM, Mavromichalis S, Chang M, Contreras A, Rosenberg Y, Kirby R, Bhargava B, Senior R, Banfield A, Goodman SG, Lopes RD, Pracoń R, López-Sendón J, Maggioni AP, Newman JD, Berger JS, Sidhu MS, White HD, Troxel AB, Harrington RA, Boden WE, Stone GW, Mark DB, Spertus JA, Maron DJ, Hochman JS, Maron DJ, Reynolds HR, Bangalore S, Mavromichalis S, Chang M, Contreras A, Esquenazi-Karonika S, Gilsenan M, Gwiszcz E, Mathews P, Mohamed S, Naumova A, Roberts A, VanLoo K, Anthopolos R, Xu Y, Troxel AB, Lu Y, Huang Z, Broderick S, Guzmán L, Selvanayagam J, Lopes RD, Goodman SG, Steg G, Juliard J-M, Doerr R, Keltai M, Bhargava B, Thomas B, Sharir T, Nikolsky E, Maggioni AP, Kohsaka S, Escobedo J, White HD, Pracoń R, Bockeria O, López-Sendón J, Held C, Senior R, Banfield A, Shaw LJ, Phillips L, Berman D, Kwong RY, Picard MH, Chaitman BR, Ali Z, Min J, Mancini GBJ, Leipsic J, Guzmán L, Hillis G, Thambar S, Joseph M, Selvanayagam J, Beltrame J, Lang I, Schuchlenz H, Huber K, Goetschalckx K, Hueb W, Caramori PR, De Quadros A, Smanio P, Mesquita C, Lopes RD, Vitola J, others. 2023. Survival After Invasive or Conservative Management of Stable Coronary Disease. Circulation 147:8–19.
1.
Guedeney P, Roule V, Mesnier J, Chapelle C, Portal J-J, Laporte S, Ollier E, Zeitouni M, Kerneis M, Procopi N, Barthelemy O, Sorrentino S, Mihalovic M, Silvain J, Vicaut E, Montalescot G, Collet J-P. 2023. Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy 9:251–261.
1.
Goodman SG, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Diaz R, Garon G, Harrington RA, Jukema JW, Manvelian G, Stipek W, Szarek M, White HD, Schwartz GG, for the OOI. 2023. Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial. Journal of the American Heart Association 12:e029216.
1.
Durand-Zaleski I, Ducrocq G, Mimouni M, Frenkiel J, Avendano-Solá C, Gonzalez-Juanatey JR, Ferrari E, Lemesle G, Puymirat E, Berard L, Cachanado M, Arnaiz JA, Martínez-Sellés M, Silvain J, Ariza-Solé A, Calvo G, Danchin N, Paco S, Drouet E, Abergel H, Rousseau A, Simon T, Steg PG. 2023. Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost–effectiveness and cost–utility analyses. European Heart Journal - Quality of Care and Clinical Outcomes 9:194–202.
1.
Coisne A, Rodés-Cabau J, Ludwig S, Scotti A, Mesnier J, Vahl TP, Ranard LS, Evans MC, Modine T, Granada JF. 2023. Impact of a Dedicated Transseptal Transcatheter Mitral Valve Replacement System on Cardiac Remodeling and Hemodynamics. JACC: Cardiovascular Interventions 16:1310–1312.
1.
Costa F, Montalto C, Branca M, Hong S-J, Watanabe H, Franzone A, Vranckx P, Hahn J-Y, Gwon H-C, Feres F, Jang Y, De Luca G, Kedhi E, Cao D, Steg PG, Bhatt DL, Stone GW, Micari A, Windecker S, Kimura T, Hong M-K, Mehran R, Valgimigli M. 2023. Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials. European Heart Journal 44:954–968.
1.
Clapp L, Giembycz M, Heinemann A, Jones RL, Narumiya S, Norel X, Sugimoto Y, Woodward DF, Yao C. 2023. Prostanoid receptors in GtoPdb v.2023.1. IUPHAR/BPS Guide to Pharmacology CITE 2023.
1.
Carson JL, Brooks MM, Chaitman BR, Alexander JH, Goodman SG, Bertolet M, Abbott JD, Cooper HA, Rao SV, Triulzi DJ, Fergusson DA, Kostis WJ, Noveck H, Simon T, Steg PG, DeFilippis AP, Goldsweig AM, Lopes RD, White H, Alsweiler C, Morton E, Hébert PC, Carson JL, Ghafghazi S, Cooper HA, Wood F, Menegus M, Uretsky B, Vallurupalli S, Maniatis G, Gruberg L, Roswell R, Rossi J, Abtahian F, Tessalee M, Barsness G, Abbott JD, Aronow H, Ramanathan K, Schmidhofer M, Keating F, Carson M, Kontos M, Qureshi M, Clegg S, Laskey W, Polonsky T, Gupta R, Sheikh MA, Uhl L, Mullen P, Bracey A, Matthai W, Stowell C, Dudzinski D, Marhefka G, Weinstock P, Lawson W, Keller N, Yuriditsky E, Thomas M, Jacobs A, Hochberg C, Siddiqi O, Schulman-Marcus J, Torosoff M, Gitter M, Dai X, Traverse J, McCamant E, Scott J, Swaminathan R, Rao S, Goldsweig AM, DeFilippis AP, Salisbury A, Landers D, Raveendran G, Ebrahimi R, Bach R, Delehanty J, Shah RC, Brener S, Doroshow J, Caixeta A, Precoma D, Dall’Orto FTC, De Andrade PB, Dracoulakis M, Maia LN, Ritt LEF, Quadros A, Filho DCS, De Martino F, Huynh T, Schnell G, Senaratne M, Tandon V, Tandon V, Neary J, others. 2023. Rationale and design for the myocardial ischemia and transfusion (MINT) randomized clinical trial. American Heart Journal 257:120–129.
1.
Bouhadoun A, Manikpurage HD, Deschildre C, Zalghout S, Dubourdeau M, Urbach V, Ho-Tin-Noe B, Deschamps L, Michel J-B, Longrois D, Norel X. 2023. DHA, RvD1, RvD5, and MaR1 reduce human coronary arteries contractions induced by PGE2. Prostaglandins & Other Lipid Mediators 165:106700.
1.
Bikdeli B, Erlinge D, Valgimigli M, Kastrati A, Han Y, Steg PG, Stables RH, Mehran R, James SK, Frigoli E, Goldstein P, Li Y, Shahzad A, Schüpke S, Mehdipoor G, Chen S, Redfors B, Crowley A, Zhou Z, Stone GW. 2023. Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials. Circulation 148:1207–1219.
1.
Benseba J, Mercier J, Couture T, Faroux L, Bernatchez L, Côté M, Panagides V, Mesnier J, Mohammadi S, Dumont É, Kalavrouziotis D, Hadjadj S, Beaudoin J, DeLarochellière R, Rodés-Cabau J, Paradis J-M. 2023. Fractional Flow Reserve to Assess Coronary Artery Disease in Patients with Severe Aortic Stenosis Undergoing Transcatheter Aortic Valve Implantation: Long-Term Outcomes. Structural Heart 7:100179.
1.
Belhassen M, Hanon O, Steg PG, Mahé I, Née M, Jacoud F, Dalon F, Cotté F-E, Guitard-Dehoux D, Marant-Micallef C, Van Ganse E, Danchin N. 2023. Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France. The European Journal of Health Economics 24:867–875.
1.
Baugh CW, Freund Y, Steg PG, Body R, Maron DJ, Yiadom MYAB. 2023. Strategies to mitigate emergency department crowding and its impact on cardiovascular patients. European Heart Journal: Acute Cardiovascular Care 12:633–643.
1.
Alexander SPH, Christopoulos A, Davenport AP, Kelly E, Mathie AA, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Davies JA, Abbracchio MP, Abraham G, Agoulnik A, Alexander W, Al‐hosaini K, Bäck M, Baker JG, Barnes NM, Bathgate R, Beaulieu J, Beck‐Sickinger AG, Behrens M, Bernstein KE, Bettler B, Birdsall NJM, Blaho V, Boulay F, Bousquet C, Bräuner‐Osborne H, Burnstock G, Caló G, Castaño JP, Catt KJ, Ceruti S, Chazot P, Chiang N, Chini B, Chun J, Cianciulli A, Civelli O, Clapp LH, Couture R, Cox HM, Csaba Z, Dahlgren C, Dent G, Douglas SD, Dournaud P, Eguchi S, Escher E, Filardo EJ, Fong T, Fumagalli M, Gainetdinov RR, Garelja ML, De Gasparo M, Gerard C, Gershengorn M, Gobeil F, Goodfriend TL, Goudet C, Grätz L, Gregory KJ, Gundlach AL, Hamann J, Hanson J, Hauger RL, Hay DL, Heinemann A, Herr D, Hollenberg MD, Holliday ND, Horiuchi M, Hoyer D, Hunyady L, Husain A, Ijzerman AP, Inagami T, Jacobson KA, Jensen RT, Jockers R, Jonnalagadda D, Karnik S, Kaupmann K, Kemp J, Kennedy C, Kihara Y, Kitazawa T, Kozielewicz P, Kreienkamp H, Kukkonen JP, Langenhan T, Larhammar D, Leach K, Lecca D, Lee JD, Leeman SE, Leprince J, Li XX, others. 2023. The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors. British Journal of Pharmacology 180.
1.
Abtan J, Bhatt DL, Elbez Y, Ducrocq G, Goto S, Smith SC, Ohman EM, Eagle KA, Fox K, Harrington RA, Leiter LA, Mehta SR, Simon T, Petrov I, Sinnaeve PR, Pais P, Lev E, Bueno H, Wilson P, Steg PG. 2023. External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry. International Journal of Cardiology 370:51–57.
1.
Abdelazeem H, Tu L, Thuillet R, Ottaviani M, Boulfrad A, Beck T, Senbel A, Mani S, Castier Y, Guyard A, Tran-Dinh A, El-Benna J, Longrois D, Silverstein AM, Guignabert C, Norel X. 2023. AMPK activation by metformin protects against pulmonary hypertension in rats and relaxes isolated human pulmonary artery. European Journal of Pharmacology 946:175579.

2022

1.
White HD, Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Chiang C-E, Diaz R, Goodman SG, Jukema JW, Loy M, Pagidipati N, Pordy R, Ristić AD, Zeiher AM, Wojdyla DM, Steg PG, for the OOI. 2022. Alirocumab after acute coronary syndrome in patients with a history of heart failure. European Heart Journal 43:1554–1565.
1.
Weintraub WS, Bhatt DL, Zhang Z, Dolman S, Boden WE, Bress AP, King JB, Bellows BK, Tajeu GS, Derington CG, Johnson J, Andrade K, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif J-C, Ballantyne CM, Kolm P. 2022. Cost-effectiveness of Icosapent Ethyl for High-risk Patients With Hypertriglyceridemia Despite Statin Treatment. JAMA Network Open 5:e2148172.
1.
Wargny M, Croyal M, Ragot S, Gand E, Jacobi D, Trochu J-N, Prieur X, Le May C, Goronflot T, Cariou B, Saulnier P-J, Hadjadj S, for the S study group, Marechaud R, Javaugue V, Hulin-Delmotte C, Llatty P, Ducrocq G, Roussel R, Rigalleau V, Pucheu Y, Montaigne D, Halimi J-M, Gatault P, Sosner P, Gellen B. 2022. Nutritional biomarkers and heart failure requiring hospitalization in patients with type 2 diabetes: the SURDIAGENE cohort. Cardiovascular Diabetology 21:101.
1.
Tea V, Morelle J-F, Gallet R, Cayla G, Lemesle G, Lhermusier T, Dillinger J-G, Ducrocq G, Angouvant D, Cottin Y, Chamandi C, Le Bras A, Steg PG, Montalescot G, Nelson AC, Simon T, Chatellier G, Danchin N, Puymirat E. 2022. Immediate versus staged complete myocardial revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease: A post hoc analysis of the randomized FLOWER-MI trial. Archives of Cardiovascular Diseases 115:496–504.
1.
Steg PG, Bhatt DL, James SK, Darlington O, Hoskin L, Simon T, Fox KM, Leiter LA, Mehta SR, Harrington RA, Himmelmann A, Ridderstråle W, Andersson M, Bueno H, De Luca L, Tank A, Mellström C, McEwan P. 2022. Cost–effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial. European Heart Journal - Cardiovascular Pharmacotherapy 8:777–785.
1.
Spyropoulos AC, Raskob GE, Cohen AT, Ageno W, Weitz JI, Spiro TE, Lu W, Lipardi C, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard G, Steg PG, Sugarmann C, Barnathan ES. 2022. Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation 145:1471–1479.
1.
Spyropoulos AC, Goldin M, Ageno W, Albers GW, Elliott CG, Hiatt WR, Halperin JL, Maynard G, Steg PG, Weitz JI, Spiro TE, Lu W, Marsigliano J, Raskob GE, Barnathan ES. 2022. Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial. TH Open 06:e177–e183.
1.
Singh N, Bhatt DL, Miller M, Steg PG, Brinton EA, Jacobson TA, Jiao L, Tardif J-C, Mason RP, Ballantyne CM. 2022. Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT. Journal of the American College of Cardiology 79:220–222.
1.
Sidhu MS, Alexander KP, Huang Z, O’Brien SM, Chaitman BR, Stone GW, Newman JD, Boden WE, Maggioni AP, Steg PG, Ferguson TB, Demkow M, Peteiro J, Wander GS, Phaneuf DC, De Belder MA, Doerr R, Alexanderson-Rosas E, Polanczyk CA, Henriksen PA, Conway DSG, Miro V, Sharir T, Lopes RD, Min JK, Berman DS, Rockhold FW, Balter S, Borrego D, Rosenberg YD, Bangalore S, Reynolds HR, Hochman JS, Maron DJ. 2022. Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial. American Heart Journal 248:72–83.
1.
Selvaraj S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Juliano RA, Jiao L, Tardif J, Ballantyne CM, the RI. 2022. Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE‐IT. Journal of the American Heart Association 11:e024999.
1.
Schwartz GG, Szarek M, Zeiher A, White HD, Jukema JW, Harrington RA, Goodman SG, Diaz R, Bittner V, Bhatt DL, Steg PG. 2022. Elevated C-Reactive Protein Amplifies Association of Lipoprotein(a) With Cardiovascular Risk and Clinical Benefit of Alirocumab. Journal of the American College of Cardiology 80:2356–2359.
1.
Sebag FS, Garot P, Galea R, De Backer O, Lepillier A, De Meesteer A, Hildick-Smith D, Armero S, Moubarak G, Ducrocq G, Eschalier R, Aminian A, Sauguet A, Lellouche N, Mahmoudi K, Räber L, Amabile N. 2022. Left atrial appendage closure for thrombus trapping: the international, multicentre TRAPEUR registry. EuroIntervention 18:50–57.
1.
Sardella G, Beerkens FJ, Dangas G, Cao D, Baber U, Sartori S, Cohen DJ, Briguori C, Gil R, Nicolas J, Zhang Z, Dudek D, Kunadian V, Kornowski R, Weisz G, Claessen B, Marx S, Escaned J, Huber K, Collier T, Moliterno DJ, Ohman EM, Krucoff MW, Kastrati A, Steg PG, Angiolillo DJ, Mehta S, Shlofmitz R, Sharma S, Pocock S, Gibson CM, Mehran R. 2022. Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. EuroIntervention 18:e897–e909.
1.
Rosso C, Moulton Jr Eric, Kemlin C, Leder S, Corvol J-C, Mehdi S, Obadia MA, Obadia M, Yger M, Meseguer E, Perlbarg V, Valabregue R, Magno S, Lindberg P, Meunier S, Lamy J-C. 2022. Cerebello-Motor Paired Associative Stimulation and Motor Recovery in Stroke: a Randomized, Sham-Controlled, Double-Blind Pilot Trial. Neurotherapeutics 19:491–500.
1.
Rodés-Cabau J, Ibrahim R, De Larochellière R, Ben Ali W, Paradis J-M, Robichaud S, Dorval J-F, Mohammadi S, Dumont E, Kalavrouziotis D, Mesnier J, Panagides V, Picard-Deland M, Lalancette S, Pelletier-Beaumont E. 2022. A pressure wire for rapid pacing, valve implantation and continuous haemodynamic monitoring during transcatheter aortic valve implantation procedures. EuroIntervention 18:e345–e348.
1.
Robert R, Cottin Y, Potard V, Mary-Krause M, Lang S, Teiger E, Collet JP, Chauvet-Droit M, Ederhy S, Soulat-Dufour L, Ancedy Y, Adavane-Scheuble S, Nhan P, Steg PG, Funck-Brentano C, Costagliola D, Cohen A, Boccara F, on behalf the P-HIVI. 2022. Coronary Angiographic Features and Major Adverse Cardiac or Cerebrovascular Events in People Living With Human Immunodeficiency Virus Presenting With Acute Coronary Syndrome. Circulation: Cardiovascular Interventions 15.
1.
Ridker PM, Rifai N, MacFadyen J, Glynn RJ, Jiao L, Steg PG, Miller M, Brinton EA, Jacobson TA, Tardif J-C, Ballantyne CM, Mason RP, Bhatt DL. 2022. Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy. Circulation 146:372–379.
1.
Raskob GE, Ageno W, Albers G, Elliott CG, Halperin J, Maynard G, Steg PG, Weitz JI, Albanese J, Yuan Z, Levitan B, Lu W, Suh EY, Spiro T, Lipardi C, Barnathan ES, Spyropoulos AC. 2022. Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness. Journal of the American Heart Association 11:e026229.
1.
Psychogios M, Brehm A, López-Cancio E, Marco De Marchis G, Meseguer E, Katsanos AH, Kremer C, Sporns P, Zedde M, Kobayashi A, Caroff J, Bos D, Lémeret S, Lal A, Arenillas JF. 2022. European Stroke Organisation guidelines on treatment of patients with intracranial atherosclerotic disease. European Stroke Journal 7:XLII–LXXX.
1.
Pollack CV, Steg PG, James S, Jolly S, Kosiborod M, Bonaca MP. 2022. International Perspectives on the Impact of the COVID-19 Pandemic on Adherence to Prescribed Dual Antiplatelet Therapy: A Window Into Acute Cardiovascular Care. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 21:114–122.
1.
Pitt B, Steg G, Leiter LA, Bhatt DL. 2022. The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Cardiovascular Drugs and Therapy 36:561–567.
1.
Pitt B, Steg G, Leiter LA, Bhatt DL. 2022. Response to the Letter on “The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus.” Cardiovascular Drugs and Therapy 36:573–573.
1.
Pitt B, Steg G, Leiter LA, Bhatt DL. 2022. Correction to: The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Cardiovascular Drugs and Therapy 36:1259–1259.
1.
Pham V, Bonnet M, Varenne O, Lafont A, Darmon A, Feldman L, Rioufol G, Derimay F, Harbaoui B, Picard F. 2022. In-Stent Use of Intravascular Coronary Lithotripsy for Restenosis and Stent Underexpansion: A Multicentre Experience. Canadian Journal of Cardiology 38:1474–1475.
1.
Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, Mann DL, McMurray JJV, Rouleau J-L, Solomon SD, Steg PG, Berwanger O, Cikes M, De Pasquale CG, Fernandez A, Filippatos G, Jering K, Landmesser U, Menon V, Merkely B, Petrie MC, Petrov I, Schou M, Senni M, Sim D, Van Der Meer P, Lefkowitz M, Zhou Y, Wang Y, Braunwald E. 2022. Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation 145:87–89.
1.
Peterson BE, Harrington RA, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Lopes RD, Leonardi S, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL. 2022. Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. Circulation: Cardiovascular Interventions 15.
1.
Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif J, Verma S, Ballantyne CM, the RI. 2022. Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI. Journal of the American Heart Association 11:e022937.
1.
Perera KS, De Sa Boasquevisque D, Rao-Melacini P, Taylor A, Cheng A, Hankey GJ, Lee S, Fabregas JM, Ameriso SF, Field TS, Arauz A, Coutts SB, Arnold M, Mikulik R, Toni D, Mandzia J, Veltkamp RC, Meseguer E, Haeusler KG, Hart RG, Young EI, Ameriso S, Dossi D, Rodriguez Lucci F, Rosales J, Gomez Schneider M, Soledad Rodriguez M, Javier Alet M, Pujol Lereis V, Pablo Povedano G, Veronica Marroquin M, Wijeratne T, Mackey E, Warburton E, Rezania F, Kleinig T, Kelly E, Harvey J, Nayar S, Perera K, Field T, Coutts S, Tse D, Smith E, Teleg E, Hill M, Signh R, Mandzia J, Pikula A, Stotts G, Olavarria V, Mazzon E, Meseguer E, Pico F, Kallmuenzer B, Koehn J, Macha K, Roeder S, Nolte C, Randus I, Bader J, Geran R, Tuetuencue S, Seidel G, Detmar K, Arauz Gongora AA, Czlonkowska A, Kozera D, Gluszkiewicz M, Karlinski M, Brola W, Ziomek M, Basson M, Pretorius M, Francisco Arenillas J, Cortijo Garcia E, Marti-Fabregas J, Gomis M, Munoz L, Arnold M, Maamari B, Vynckier J, Goldlin M, Jung S, Horvath T, Meinel T, Markus H, Chembala J, Roffe C, Weerathunga J, Abano N, Ferdinand P, Veltkamp R, Malik A, Ali Sheikh A, D’Anna L, Halse O, Banerjee S, Bojaryn U, Ali A, others. 2022. Evaluating Rates of Recurrent Ischemic Stroke Among Young Adults With Embolic Stroke of Undetermined Source: The Young ESUS Longitudinal Cohort Study. JAMA Neurology 79:450.
1.
Pascual I, Hernández-Vaquero D, Alperi A, Almendarez M, Avanzas P, Kalavrouziotis D, Lorca R, Mesnier J, Arboine L, Mohammadi S, Valle RD, Dumont E, Leon V, De Larochelliere R, Rodés-Cabau J, Moris C. 2022. Permanent Pacemaker Reduction Using Cusp-Overlapping Projection in TAVR. JACC: Cardiovascular Interventions 15:150–161.
1.
Panagides V, Mesnier J, Nuche J, Delarochellière R, Paradis J-M, Kalavrouziotis D, Dumont E, Mohammadi S, Rodes-Cabau J. 2022. From the Evolut Pro to the Evolut FX self-expanding transcatheter aortic valve replacement systems: current status and future perspectives. Expert Review of Medical Devices 19:561–569.
1.
Panagides V, Kalavrouziotis D, Dumont E, Delarochellière R, Paradis J-M, Mesnier J, Mohammadi S, Rodés-Cabau J. 2022. Cranial nerve injury during transcarotid transcatheter aortic valve replacement. International Journal of Cardiology 353:46–48.
1.
Panagides V, Kalavrouziotis D, Dumont E, Delarochellière R, Paradis J-M, Mesnier J, Mohammadi S, Rodés-Cabau J. 2022. Carotid ultrasound following transcarotid transcatheter aortic valve replacement. International Journal of Cardiology 358:12–16.
1.
Ostadal P, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Chua T, Diaz R, Goodman SG, Huo Y, Jukema JW, Karpov Y, Pordy R, Scemama M, Szarek M, White HD, Schwartz GG. 2022. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. The Lancet Diabetes & Endocrinology 10:330–340.
1.
Ozen G, Aljesri K, Turkyilmaz G, Turkyilmaz S, Kavala AA, Topal G, Norel X. 2022. Comparative study of coronary artery bypass graft materials: reduced contraction and ADMA levels in internal mammary artery versus saphenous vein. The Journal of Cardiovascular Surgery 63.
1.
Ono M, Tomaniak M, Koenig W, Khamis R, De Silva R, Chichareon P, Kawashima H, Hara H, Gao C, Wang R, Huber K, Vrolix M, Jasionowicz P, Wykrzykowska JJ, Piek JJ, Jüni P, Hamm C, Steg PG, Windecker S, Onuma Y, Storey RF, Serruys PW. 2022. Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial. European Heart Journal - Cardiovascular Pharmacotherapy 8:39–47.
1.
Ono M, Hara H, Kawashima H, Gao C, Wang R, Wykrzykowska JJ, Piek JJ, Garg S, Hamm C, Steg PG, Valgimigli M, Windecker S, Vranckx P, Onuma Y, Serruys PS. 2022. Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial. EuroIntervention 18:e377–e388.
1.
Nuche J, Panagides V, Nault I, Mesnier J, Paradis J-M, De Larochellière R, Kalavrouziotis D, Dumont E, Mohammadi S, Philippon F, Rodés-Cabau J. 2022. Incidence and clinical impact of tachyarrhythmic events following transcatheter aortic valve replacement: A review. Heart Rhythm 19:1890–1898.
1.
Moriarty PM, Steg PG, McGinniss J, Zeiher AM, White HD, Manvelian G, Pordy R, Loy M, Jukema JW, Harrington RA, Gray JV, Gorby LK, Goodman SG, Diaz R, Bittner VA, Bhatt DL, Szarek M, Schwartz GG. 2022. Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes. Journal of Clinical Lipidology 16:747–756.
1.
Murphy WA, Lin N, Damask A, Schwartz GG, Steg PG, Szarek M, Banerjee P, Fazio S, Manvelian G, Pordy R, Shuldiner AR, Paulding C. 2022. Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial. Circulation: Genomic and Precision Medicine 15.
1.
Mikail N, Meseguer E, Lavallée P, Klein I, Hobeanu C, Guidoux C, Cabrejo L, Lesèche G, Amarenco P, Hyafil F. 2022. Evaluation of non-stenotic carotid atherosclerotic plaques with combined FDG-PET imaging and CT angiography in patients with ischemic stroke of unknown origin. Journal of Nuclear Cardiology 29:1329–1336.
1.
Mihatov N, Secemsky EA, Kereiakes DJ, Steg PG, Cutlip DE, Kirtane AJ, Mehran R, Zhao B, Song Y, Gibson CM, Yeh RW. 2022. Individualizing Dual Antiplatelet Therapy (DAPT) Duration Based on Bleeding Risk, Ischemic Risk, or Both: An Analysis From the DAPT Study. Cardiovascular Revascularization Medicine 41:105–112.
1.
Mesnier J, Rodés-Cabau J. 2022. CT-FFR in the TAVR Work-Up. JACC: Cardiovascular Interventions 15:1150–1152.
1.
Mesnier J, Panagides V, Nuche J, Rodés-Cabau J. 2022. Evolving Indications of Transcatheter Aortic Valve Replacement—Where Are We Now, and Where Are We Going. Journal of Clinical Medicine 11:3090.
1.
Mesnier J, Cruz-González I, Arzamendi D, Freixa X, Nombela-Franco L, Peral V, Caneiro-Queija B, Mangieri A, Trejo-Velasco B, Asmarats L, Regueiro A, McInerney A, Mas-Lladó C, Estevez-Loureiro R, Laricchia A, O’Hara G, Rodés-Cabau J. 2022. Early Discontinuation of Antithrombotic Treatment Following Left Atrial Appendage Closure. The American Journal of Cardiology 171:91–98.
1.
Mesnier J, Cruz-González I, Arzamendi D, Freixa X, Nombela-Franco L, Peral V, Caneiro-Queija B, Mangieri A, Trejo-Velasco B, Asmarats L, Regueiro A, McInerney A, Mas-Lladó C, Estevez-Loureiro R, Laricchia A, O’Hara G, Rodés-Cabau J. 2022. Incidence and Predictors of Early Death in Patients Undergoing Percutaneous Left Atrial Appendage Closure. JACC: Clinical Electrophysiology 8:1093–1102.
1.
Mehta SR, Wang J, Wood DA, Spertus JA, Cohen DJ, Mehran R, Storey RF, Steg PG, Pinilla-Echeverri N, Sheth T, Bainey KR, Bangalore S, Cantor WJ, Faxon DP, Feldman LJ, Jolly SS, Kunadian V, Lavi S, Lopez-Sendon J, Madan M, Moreno R, Rao SV, Rodés-Cabau J, Stanković G, Bangdiwala SI, Cairns JA, Investigators CT, Amerena J, Farshid A, Zeitz C, Duffy S, Stub D, Freeman M, Lang I, Pourbaix S, Guedes A, Kormann A, Caramori P, Nicolau JC, Santos M, Marin-Neto JA, Kerr Saraiva JF, Costa JDR, Welsh R, Bhagirath K, Kassam SA, Della Siega A, Džavík V, Boone R, Cheema A, Traboulsi M, Teskey R, Vuurmans T, Ducas J, Cohen E, Nguyen M, Généreux P, Schampaert E, Kim HH, Nadeem N, Kokis A, Ball W, Dehghani P, Wong B, Sussex B, Mansour S, Dighe K, Pelletier J-P, Wu Y, Cheng X-S, Wang Q, Shaobin J, Yitong M, Yuehui Y, Wu W, Zheng Q, Fu Q, Vesga B, Hlinomaz O, Niemelä K, Varenne O, Feldman L, Dubreuil O, Dillinger JG, Ferrari E, Nallet O, Bruder O, Hahalis G, Ziakas A, Voudris V, Kőszegi Z, Horvath I, Fuchs S, Kapeliovich M, D’Ascenzo F, Di Pasquale G, Guiducci V, Campo G, Varbella F, Al Khdair D, others. 2022. Complete Revascularization vs Culprit Lesion–Only Percutaneous Coronary Intervention for Angina-Related Quality of Life in Patients With ST-Segment Elevation Myocardial Infarction: Results From the COMPLETE Randomized Clinical Trial. JAMA Cardiology 7:1091.
1.
Mehran R, Steg PG, Pfeffer MA, Jering K, Claggett B, Lewis EF, Granger C, Køber L, Maggioni A, Mann DL, McMurray JJV, Rouleau J-L, Solomon SD, Ducrocq G, Berwanger O, De Pasquale CG, Landmesser U, Petrie M, Leng DSK, Van Der Meer P, Lefkowitz M, Zhou Y, Braunwald E. 2022. The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial. Circulation 146:1749–1757.
1.
Mariette X, Hermine O, Tharaux P-L, Resche-Rigon M, Porcher R, Ravaud P, Bureau S, Dougados M, Tibi A, Azoulay E, Cadranel J, Emmerich J, Fartoukh M, Guidet B, Humbert M, Lacombe K, Mahevas M, Pene F, Pourchet-Martinez V, Schlemmer F, Yazdanpanah Y, Baron G, Perrodeau E, Vanhoye D, Kedzia C, Demerville L, Gysembergh-Houal A, Bourgoin A, Dalibey S, Raked N, Mameri L, Alary S, Hamiria S, Bariz T, Semri H, Hai DM, Benafla M, Belloul M, Vauboin P, Flamand S, Pacheco C, Walter-Petrich A, Stan E, Benarab S, Nyanou C, Montlahuc C, Biard L, Charreteur R, Dupré C, Cardet K, Lehmann B, Baghli K, Madelaine C, D’Ortenzio E, Puéchal O, Semaille C, Savale L, Harrois A, Figueiredo S, Duranteau J, Anguel N, Pavot A, Monnet X, Richard C, Teboul J-L, Durand P, Tissieres P, Jevnikar M, Montani D, Bulifon S, Jaïs X, Sitbon O, Pavy S, Noel N, Lambotte O, Escaut L, Jauréguiberry S, Baudry E, Verny C, Noaillon M, Lefèvre E, Zaidan M, Le Tiec CLT, Verstuyft C, Roques A-M, Grimaldi L, Molinari D, Leprun G, Fourreau A, Cylly L, Virlouvet M, Meftali R, Fabre S, Licois M, Mamoune A, Boudali Y, Georgin-Lavialle S, Senet P, Pialoux G, Soria A, others. 2022. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. The Lancet Rheumatology 4:e24–e32.
1.
Mak K-H, Vidal-Petiot E, Young R, Sorbets E, Greenlaw N, Ford I, Tendera M, Ferrari R, Tardif J-C, Udell JA, Escobedo J, Fox KM, Steg PG, the CI. 2022. Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities. European Journal of Preventive Cardiology 28:1795–1806.
1.
Lopes RD, Guimarães PO, Schwartz GG, Bhatt DL, Bittner VA, Budaj A, Dalby AJ, Diaz R, Goodman SG, Harrington RA, Jukema JW, Kiss RG, Loy M, Pordy R, Poulouin Y, Szarek M, White HD, Steg PG. 2022. Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial. The American Journal of Medicine 135:915–918.

2021

1.
Zeymer U, Leiva O, Hohnloser SH, Steg PG, Oldgren J, Nickenig G, Gabor Kiss R, Ongen Z, Navarro Estrada J, Oude Ophuis T, Lip GYH, Nordaby M, Miede C, Ten Berg JM, Bhatt DL, Cannon CP. 2021. Dual antithrombotic therapy with dabigatran in patients with atrial fibrillation after percutaneous coronary intervention for ST-segment elevation myocardial infarction: a post hoc analysis of the randomised RE-DUAL PCI trial. EuroIntervention 17:474–480.
1.
White HD, Steg PG, Schwartz GG. 2021. Myocardial Infarction and Evolocumab. JAMA Cardiology 6:1220.
1.
Vranckx P, Valgimigli M, Odutayo A, Serruys PW, Hamm C, Steg PG, Heg D, Mc Fadden EP, Onuma Y, Benit E, Janssens L, Diletti R, Ferrario M, Huber K, Räber L, Windecker S, Jüni P, the GLI. 2021. Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre‐Specified Analysis of the GLOBAL LEADERS Trial. Journal of the American Heart Association 10:e015560.
1.
Viedma-Guiard E, Guidoux C, Amarenco P, Meseguer E. 2021. Aortic Sources of Embolism. Frontiers in Neurology 11:606663.
1.
Verma S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Dhingra NK, Ketchum SB, Juliano RA, Jiao L, Doyle RT, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Mason RP, Tardif J-C, Ballantyne CM, Bhatt DL, Ballantyne CM, Brinton EA, Jacobson TA, Miller M, Steg PG, Tardif J-C, Martens FMAC, Schut A, Olshansky B, Chung M, Hallstrom A, Pearce L, Mehta C, Mukherjee R, Gibson CM, Chakrabarti AK, Gelfand EV, Giugliano RP, Leary MC, Pinto DS, Pride YB, Ketchum S, Bhavanthula R, Chester G, Copland C, Diffin K, Doyle R, Erz K, Giaquinto A, Glanton P, Granger A, Granowitz C, Iroudayassamy RH, Jiao L, Juliano R, Jin J, Klevak D, Panchal H, Wang R, Wang S-R, Abate G, Berry PJ, Braeckman R, Doogan D, Elson A, HauptmannBaker A, Lamela I, Lubeck C, Manku M, Murphy S, Sanford M, Stirtan W, Soni P, Bastien A, Foster D, Gascon E, Johnson J, Latona L, Liu G, Palleja S, Sanjuan N, Shi J, Stager W, Venkatakrishnan M, Youssef-Agha A, Zhu J, Aertker L, Ankolekar S, Goldberg L, Rajicic N, Shu J, Zou H, Mikhail M, Dawood G, Koshy NM, Mukherjee SK, Abadier R, Lawless AL, McGuinn WP, Weintraub H, others. 2021. Icosapent Ethyl Reduces Ischemic Events in Patients With a History of Previous Coronary Artery Bypass Grafting: REDUCE-IT CABG. Circulation 144:1845–1855.
1.
Valgimigli M, Mehran R, Franzone A, Da Costa BR, Baber U, Piccolo R, McFadden EP, Vranckx P, Angiolillo DJ, Leonardi S, Cao D, Dangas GD, Mehta SR, Serruys PW, Gibson CM, Steg GP, Sharma SK, Hamm C, Shlofmitz R, Liebetrau C, Briguori C, Janssens L, Huber K, Ferrario M, Kunadian V, Cohen DJ, Zurakowski A, Oldroyd KG, Yaling H, Dudek D, Sartori S, Kirkham B, Escaned J, Heg D, Windecker S, Pocock S, Jüni P, Valgimigli M, Mehran R, Windecker S, Vranckx P, Serruys P, Steg GP, Hamm C, Baber U, Angiolillo DJ, Cohen DJ, Dangas GD, Mehta S, Gibson MC, Kastrati A, Krucoff M, Ohman ME, Gurbel P, Henry TD, Moliterno D, Sharma SK, Pocock S, Jüni P, Da Costa BR, Kirkham B, Sartori S, Heg D, McFadden E, Leonardi S, Piccolo R, Franzone A, Marx SO, Darrow B, Corvaja N, DeStefano D, Ghodsi N, Meller J, Franklin-Bond T, Cha JY, Waseem Z, Jüni P, Da Costa BR, Kirkham B, Huber K, Weisz G, Kornowski R, Kunadian V, Oldroyd K, Yaling H, Kaul U, Witzenbichler B, Dzavik V, Gil R, Dudek D, Sardella G, Escaned J, Shlofmitz R, Briguori C, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, others. 2021. Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. JACC: Cardiovascular Interventions 14:444–456.
1.
Urena M, Vahanian A, Brochet E, Ducrocq G, Iung B, Himbert D. 2021. Current Indications for Transcatheter Mitral Valve Replacement Using Transcatheter Aortic Valves: Valve-in-Valve, Valve-in-Ring, and Valve-in-Mitral Annulus Calcification. Circulation 143:178–196.
1.
Touir A, Boumiza S, Nasr HB, Bchir S, Tabka Z, Norel X, Chahed K. 2021. Prostaglandin Endoperoxide H Synthase-2 (PGHS-2) Variants and Risk of Obesity and Microvascular Dysfunction Among Tunisians: Relevance of rs5277 (306G/C) and rs5275 (8473T/C) Genetic Markers. Biochemical Genetics 59:1457–1486.
1.
Urena M, Lemann T, Chong‐Nguyen C, Brochet E, Ducrocq G, Carrasco J, Iung B, Vahanian A, Himbert D. 2021. Causes and predictors of mortality after transcatheter mitral valve implantation in patients with severe mitral annulus calcification. Catheterization and Cardiovascular Interventions 98:981–989.
1.
Thomas MR, James SK, Becker RC, Himmelmann A, Katus HA, Cannon CP, Steg PG, Siegbahn A, Lakic T, Storey RF, Wallentin L. 2021. Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. European Heart Journal Acute Cardiovascular Care 10:153–163.
1.
Tharaux P-L, Pialoux G, Pavot A, Mariette X, Hermine O, Resche-Rigon M, Porcher R, Ravaud P, Bureau S, Dougados M, Tibi A, Azoulay E, Cadranel J, Emmerich J, Fartoukh M, Guidet B, Humbert M, Lacombe K, Mahevas M, Pene F, Pourchet-Martinez V, Schlemmer F, Yazdanpanah Y, Baron G, Perrodeau E, Vanhoye D, Kedzia C, Demerville L, Gysembergh-Houal A, Bourgoin A, Dalibey S, Raked N, Mameri L, Alary S, Hamiria S, Bariz T, Semri H, Hai DM, Benafla M, Belloul M, Vauboin P, Flamand S, Pacheco C, Walter-Petrich A, Stan E, Benarab S, Nyanou C, Montlahuc C, Biard L, Charreteur R, Dupré C, Cardet K, Lehmann B, Baghli K, Madelaine C, D’Ortenzio E, Puéchal O, Semaille C, Savale L, Harrois A, Figueiredo S, Duranteau J, Anguel N, Monnet X, Richard C, Teboul J-L, Durand P, Tissieres P, Jevnikar M, Montani D, Bulifon S, Jaïs X, Sitbon O, Pavy S, Noel N, Lambotte O, Escaut L, Jauréguiberry S, Baudry E, Verny C, Noaillon M, Lefèvre E, Zaidan M, Le Tiec CLT, Verstuyft CV, Roques A-M, Grimaldi L, Molinari D, Leprun G, Fourreau A, Cylly L, Virlouvet M, Meftali R, Fabre S, Licois M, Mamoune A, Boudali Y, Georgin-Lavialle S, Senet P, Soria A, others. 2021. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. The Lancet Respiratory Medicine 9:295–304.
1.
Tan JWC, Chew DP, Tsui KL, Tan D, Duplyakov D, Hammoudeh A, Zhang B, Li Y, Xu K, Ong PJ, Firman D, Gamra H, Almahmeed W, Dalal J, Tam L-W, Steg G, Nguyen QN, Ako J, Al Suwaidi J, Chan M, Sobhy M, Shehab A, Buddhari W, Wang Z, Fong AYY, Karadag B, Kim B-K, Baber U, Chin CT, Han YL. 2021. 2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations. European Cardiology Review 16:e43.
1.
Sulman D, Darmon A, Ducrocq G. 2021. A giant left ventricular calcified pseudoaneurysm 24 years following acute myocardial infarction: a case report. European Heart Journal - Case Reports 5:ytab329.
1.
Szarek M, Bhatt DL, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Banks P, Tesfaye E, Ezekowitz JA, Verma S, Pitt B, committees S-W, investigators. 2021. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure: A Randomized Trial. Annals of Internal Medicine 174:1065–1072.
1.
Steg PG, Bhatt DL. 2021. The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl. European Heart Journal 42:4865–4866.
1.
Schwartz GG, Szarek M, Bittner VA, Bhatt DL, Diaz R, Goodman SG, Jukema JW, Loy M, Manvelian G, Pordy R, White HD, Steg PG, Committees OO, Investigators, Schwartz GG, Steg PG, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Szarek M, White HD, Zeiher AM, Tricoci P, Roe MT, Mahaffey KW, Edelberg JM, Hanotin C, Lecorps G, Moryusef A, Pordy R, Sasiela WJ, Tamby J-F, Aylward PE, Drexel H, Sinnaeve P, Dilic M, Lopes RD, Gotcheva NN, Prieto J-C, Yong H, López-Jaramillo P, Pećin I, Reiner Z, Ostadal P, Viigimaa M, Nieminen MS, Chumburidze V, Marx N, Danchin N, Liberopoulos E, Montenegro Valdovinos PC, Tse H-F, Kiss RG, Xavier D, Zahger D, Valgimigli M, Kimura T, Kim HS, Kim S-H, Erglis A, Laucevicius A, Kedev S, Yusoff K, Ramos López GA, Alings M, Halvorsen S, Correa Flores RM, Budaj A, Morais J, Dorobantu M, Karpov Y, Ristic AD, Chua T, Murin J, Fras Z, Dalby AJ, Tuñón J, De Silva HA, Hagström E, Landmesser U, Chiang C-E, Sritara P, Guneri S, Parkhomenko A, Ray KK, Moriarty PM, Vogel R, Chaitman B, Kelsey SF, Olsson AG, Rouleau J-L, Simoons ML, Alexander K, Meloni C, Rosenson R, Sijbrands EJG, Tricoci P, others. 2021. Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment. Diabetes Care 44:1219–1227.
1.
Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P, Schwartz GG, Gabriel Steg P h, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Szarek M, White HD, Zeiher AM, Tricoci P, Roe MT, Mahaffey KW, Edelberg JM, Hanotin C, Lecorps G, Moryusef A, Pordy R, Sasiela WJ, Tamby J-F, Diaz R, Aylward PE, Drexel H, Sinnaeve P, Dilic M, Lopes RD, Gotcheva NN, Goodman SG, Prieto J-C, Yong H, López-Jaramillo P, Pećin I, Reiner Z, Ostadal P, Poulsen SH, Viigimaa M, Nieminen MS, Danchin N, Chumburidze V, Marx N, Liberopoulos E, Montenegro Valdovinos PC, Tse H-F, Kiss RG, Xavier D, Zahger D, Valgimigli M, Kimura T, Kim HS, Kim S-H, Erglis A, Laucevicius A, Kedev S, Yusoff K, Ramos López GA, Alings M, White HD, Halvorsen S, Correa Flores RM, Sy RG, Budaj A, Morais J, Dorobantu M, Karpov Y, Ristic AD, Chua T, Murin J, Fras Z, Dalby AJ, Tuñón J, Asita De Silva H, Hagström E, Landmesser U, Müller C, Chiang C-E, Sritara P, Guneri S, Parkhomenko A, Ray KK, Moriarty PM, Roe MT, Vogel R, Chaitman B, Kelsey SF, Olsson AG, others. 2021. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. Journal of the American College of Cardiology 78:421–433.
1.
Schwartz GG, Gabriel Steg P, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Jukema JW, Kim Y-U, Li QH, Manvelian G, Pordy R, Sourdille T, White HD, Szarek M, For the OOC, Investigators. 2021. Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score–Matched Analysis of the ODYSSEY OUTCOMES Trial. Circulation 143:1109–1122.
1.
Sacre K, Delaval L, Dossier A, Alexandra J-F, Berleur M, Chauveheid M-P, Ducrocq G, Goulenok T, Van Gysel D, Rouzaud D, Papo T. 2021. New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion. Annals of the Rheumatic Diseases 80:e190.
1.
Radiom M, Hénault R, Mani S, Iankovski AG, Norel X, Berret J-F. 2021. Magnetic wire active microrheology of human respiratory mucus https://doi.org/10.48550/ARXIV.2107.13187.
1.
Puymirat E, Cayla G, Simon T, Steg PG, Montalescot G, Durand-Zaleski I, Le Bras A, Gallet R, Khalife K, Morelle J-F, Motreff P, Lemesle G, Dillinger J-G, Lhermusier T, Silvain J, Roule V, Labèque J-N, Rangé G, Ducrocq G, Cottin Y, Blanchard D, Charles Nelson A, De Bruyne B, Chatellier G, Danchin N. 2021. Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. New England Journal of Medicine 385:297–308.
1.
Popovic B, Sorbets E, Abtan J, Cohen M, Pollack CV, Bode C, Wiviott SD, Sabatine MS, Mehta SR, Ruzyllo W, Rao SV, French WJ, Kerkar P, Kiss RG, Estrada JLN, Elbez Y, Ducrocq G, Steg PG, the TAO investigators. 2021. Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy. European Heart Journal Acute Cardiovascular Care 10:736–745.
1.
Pocock S, Brieger DB, Owen R, Chen J, Cohen MG, Goodman S, Granger CB, Nicolau JC, Simon T, Westermann D, Yasuda S, Hedman K, Mellström C, Andersson Sundell K, Grieve R. 2021. Health-related quality of life 1–3 years post-myocardial infarction: its impact on prognosis. Open Heart 8:e001499.
1.
Picard F, Bhatt DL, Ducrocq G, Ohman EM, Goto S, Eagle KA, Wilson PWF, Smith SC, Elbez Y, Steg PG. 2021. Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry. International Journal of Cardiology 340:96–104.
1.
Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, Mann DL, McMurray JJV, Rouleau J-L, Solomon SD, Steg PG, Berwanger O, Cikes M, De Pasquale CG, East C, Fernandez A, Jering K, Landmesser U, Mehran R, Merkely B, Vaghaiwalla Mody F, Petrie MC, Petrov I, Schou M, Senni M, Sim D, Van Der Meer P, Lefkowitz M, Zhou Y, Gong J, Braunwald E. 2021. Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction. New England Journal of Medicine 385:1845–1855.
1.
Picard F, Steg PG. 2021. Cardiovascular Disease Risk Reduction in Mild-Moderate Hypertriglyceridemia: Integrating Prescription of Omega-3 with Standard Treatment. Current Atherosclerosis Reports 23:27.
1.
Peterson BE, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT, Granowitz C, Gibson CM, Pinto D, Giugliano RP, Budoff MJ, Tardif J-C, Verma S, Ballantyne CM, On behalf of the R-ITI. 2021. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses. Circulation 143:33–44.
1.
Peterson BE, Bhatt DL, Gabriel Steg P, Oldgren J, Maeng M, Zeymer U, Halvorsen S, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Miede C, Kleine E, Ten Berg JM, Cannon CP. 2021. Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial. JACC: Cardiovascular Interventions 14:768–780.
1.
Peiffer-Smadja N, Bridier-Nahmias A, Ferré VM, Charpentier C, Garé M, Rioux C, Allemand A, Lavallée P, Ghosn J, Kramer L, Descamps D, Yazdanpanah Y, Visseaux B. 2021. Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2. Viruses 13:1642.
1.
Panagides V, Alperi A, Mesnier J, Philippon F, Bernier M, Rodes-Cabau J. 2021. Heart failure following transcatheter aortic valve replacement. Expert Review of Cardiovascular Therapy 19:695–709.
1.
Ozen G, Aljesri K, Abdelazeem H, Norel X, Turkyılmaz G, Turkyılmaz S, Topal G. 2021. Comparative study on the effect of aspirin, TP receptor antagonist and TxA2 synthase inhibitor on the vascular tone of human saphenous vein and internal mammary artery. Life Sciences 286:120073.
1.
Orkin AM, Gill PJ, Ghersi D, Campbell L, Sugarman J, Emsley R, Steg PG, Weijer C, Simes J, Rombey T, Williams HC, Wittes J, Moher D, Richards DP, Kasamon Y, Getz K, Hopewell S, Dickersin K, Wu T, Ayala AP, Schulz KF, Calleja S, Boutron I, Ross JS, Golub RM, Khan KM, Mulrow C, Siegfried N, Heber J, Lee N, Kearney PR, Wanyenze RK, Hróbjartsson A, Williams R, Bhandari N, Jüni P, Chan A-W, Group C, Orkin AM, Gill PJ, Ghersi D, Campbell L, Sugarman J, Emsley R, Steg PG, Weijer C, Simes J, Rombey T, Williams HC, Wittes J, Moher D, Richards DP, Kasamon Y, Getz K, Hopewell S, Dickersin K, Wu T, Ayala AP, Schulz KF, Calleja S, Boutron I, Ross JS, Golub RM, Khan KM, Mulrow C, Siegfried N, Heber J, Lee N, Kearney PR, Wanyenze RK, Hróbjartsson A, Williams R, Bhandari N, Jüni P, Chan A-W, Kiermer V, Corrigan-Curay J, Concato J. 2021. Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement. JAMA 326:257.
1.
Ono M, Kawashima H, Hara H, Gamal A, Wang R, Gao C, O’Leary N, Soliman O, Piek JJ, Geuns R, Jüni P, Hamm CW, Valgimigli M, Vranckx P, Windecker S, Steg PG, Fox KA, Onuma Y, Serruys PW. 2021. External validation of the GRACE risk score 2.0 in the contemporary all‐comers GLOBAL LEADERS trial. Catheterization and Cardiovascular Interventions ccd.29772.
1.
Olshansky B, Bhatt DL, Miller M, Steg PG, Brinton EA, Jacobson TA, Ketchum SB, Doyle Jr RT, Juliano RA, Jiao L, Granowitz C, Tardif J-C, Mehta C, Mukherjee R, Ballantyne CM, Chung MK, the R-ITI. 2021. REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results. European Heart Journal - Cardiovascular Pharmacotherapy 7:e61–e63.
1.
Obadia M, Lamirel C, Meseguer E, Seners P, Zuber K, Rosenheim M, Yavchitz A, Bidot S, Hage R, Sabben C, Savatovsky J, Lavallée PC, Gout O, Vignal C, Amarenco P. 2021. Vascular origin in acute transient visual disturbance: A prospective study. European Journal of Neurology 28:4098–4108.
1.
Mesnier J, Urena M, Chong-Nguyen C, Fischer Q, Kikoïne J, Carrasco JL, Terzian Z, Brochet E, Iung B, Himbert D. 2021. Impact of Mitral Annular Calcium and Mitral Stenosis on Outcomes After Transcatheter Aortic Valve Implantation. The American Journal of Cardiology 155:103–112.
1.
Mihatov N, Secemsky EA, Kereiakes DJ, Steg G, Serruys PW, Chichareon P, Shen C, Yeh RW. 2021. Utility of the dual antiplatelet therapy score to guide antiplatelet therapy: A systematic review and meta‐analysis. Catheterization and Cardiovascular Interventions 97:569–578.
1.
Mesnier J, Cruz-González I, Peral V, Nombela-Franco L, Freixa X, Laffond AE, Mas-Lladó C, McInerney A, Regueiro A, O’Hara G, Rodés-Cabau J. 2021. Ten-Year Outcomes Following Percutaneous Left Atrial Appendage Closure in Patients With Atrial Fibrillation and Absolute or Relative Contraindications to Chronic Anticoagulation. Circulation: Cardiovascular Interventions 14:e010821.
1.
Mesnier J, Ducrocq G, Danchin N, Ferrari R, Ford I, Tardif J-C, Tendera M, Fox KM, Steg PG, for the CI. 2021. International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study. Circulation 144:512–523.
1.
Mesnier J, Alperi A, Panagides V, Bédard E, Salaun E, Philippon F, Rodés-Cabau J. 2021. Transcatheter tricuspid valve interventions: Current devices and associated evidence. Progress in Cardiovascular Diseases 69:89–100.
1.
Marston NA, Patel PN, Kamanu FK, Nordio F, Melloni GM, Roselli C, Gurmu Y, Weng L-C, Bonaca MP, Giugliano RP, Scirica BM, O’Donoghue ML, Cannon CP, Anderson CD, Bhatt DL, Gabriel Steg P, Cohen M, Storey RF, Sever P, Keech AC, Raz I, Mosenzon O, Antman EM, Braunwald E, Ellinor PT, Lubitz SA, Sabatine MS, Ruff CT. 2021. Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. Circulation 143:470–478.
1.
Marston NA, Melloni GEM, Gurmu Y, Bonaca MP, Kamanu FK, Roselli C, Lee C, Cavallari I, Giugliano RP, Scirica BM, Bhatt DL, Steg PG, Cohen M, Storey RF, Keech AC, Raz I, Mosenzon O, Braunwald E, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CT. 2021. Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. Circulation: Genomic and Precision Medicine 14:e003006.
1.
Mariette X, Hermine O, Tharaux P-L, Resche-Rigon M, Steg PG, Porcher R, Ravaud P. 2021. Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial. JAMA Internal Medicine 181:1241.
1.
Mani S, Norel X, Varret M, Bchir S, Ben Anes A, Garrouch A, Tabka Z, Longrois D, Chahed K. 2021. Polymorphisms rs2745557 in PTGS2 and rs2075797 in PTGER2 are associated with the risk of chronic obstructive pulmonary disease development in a Tunisian cohort. Prostaglandins, Leukotrienes and Essential Fatty Acids 166:102252.
1.
Majithia A, Bhatt DL, Friedman AN, Miller M, Steg PG, Brinton EA, Jacobson TA, Ketchum SB, Juliano RA, Jiao L, Doyle RT, Granowitz C, Budoff M, Preston Mason R, Tardif J-C, Boden WE, Ballantyne CM, on behalf of the R-ITI. 2021. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL. Circulation 144:1750–1759.
1.
Magnani G, Ardissino D, Im K, Budaj A, Storey RF, Steg PG, Bhatt DL, Cohen M, Oude Ophius T, Goudev A, Parkhomenko A, Kamensky G, Angiolillo DJ, López‐Sendón J, Johanson P, Braunwald E, Sabatine MS, Bonaca MP. 2021. Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. Journal of the American Heart Association 10:e017008.
1.
Madhavan MV, Bikdeli B, Redfors B, Biondi-Zoccai G, Varunok NJ, Burton JR, Crowley A, Francese DP, Gupta A, Der Nigoghossian C, Chatterjee S, Palmerini T, Benedetto U, You SC, Ohman EM, Kastrati A, Steg PG, Gibson CM, Angiolillo DJ, Krumholz HM, Stone GW. 2021. Antiplatelet strategies in acute coronary syndromes: design and methodology of an international collaborative network meta-analysis of randomized controlled trials. Minerva Cardiology and Angiology 69.
1.
Leonardi S, Branca M, Franzone A, McFadden E, Piccolo R, Jüni P, Vranckx P, Steg PG, Serruys PW, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Heg D, Windecker S, Valgimigli M. 2021. Comparison of Investigator-Reported and Clinical Event Committee–Adjudicated Outcome Events in GLASSY. Circulation: Cardiovascular Quality and Outcomes 14:e006581.
1.
Leiter LA, Bhatt DL, McGuire DK, Teoh H, Fox K, Simon T, Mehta SR, Lev EI, Kiss RG, Dalby AJ, Bueno H, Ridderstråle W, Himmelmann A, Prats J, Liu Y, Lee JJ, Amerena J, Kosiborod MN, Steg PG. 2021. Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. Journal of the American College of Cardiology 77:2366–2377.
1.
Kosmopoulos A, Bhatt DL, Meglis G, Verma R, Pan Y, Quan A, Teoh H, Verma M, Jiao L, Wang R, Juliano RA, Kajil M, Kosiborod MN, Bari B, Berih AA, Aguilar M, Escano A, Leung A, Coelho I, Hibino M, Díaz R, Mason RP, Steg PG, Simon T, Go AS, Ambrosy AP, Choi R, Kushner AM, Leiter LA, Al-Omran M, Verma S, Mazer CD. 2021. A randomized trial of icosapent ethyl in ambulatory patients with COVID-19. iScience 24:103040.

2020

1.
Zeitouni M, Giczewska A, Lopes RD, Wojdyla DM, Christersson C, Siegbahn A, De Caterina R, Steg PG, Granger CB, Wallentin L, Alexander JH. 2020. Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. Journal of the American College of Cardiology 75:1145–1155.
1.
White HD, Stewart RAH, Dalby AJ, Stebbins A, Cannon CP, Budaj A, Linhart A, Pais P, Diaz R, Steg PG, Krug-Gourley S, Granger CB, Hochman JS, Koenig W, Harrington RA, Held C, Wallentin L. 2020. In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events. American Heart Journal 225:97–107.
1.
Westhovens R, Connolly SE, Margaux J, Vanden Berghe M, Maertens M, Van Den Berghe M, Elbez Y, Chartier M, Baeke F, Robert S, Malaise M. 2020. Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study. Rheumatology International 40:1409–1421.
1.
Van Ganse E, Danchin N, Mahé I, Hanon O, Jacoud F, Nolin M, Dalon F, Lefevre C, Cotté F-E, Gollety S, Falissard B, Belhassen M, Steg PG. 2020. Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study. Stroke 51:2066–2075.
1.
Varela LM, Meseguer E, Lapergue B, Couret D, Amarenco P, Meilhac O. 2020. Changes in High-Density Lipoproteins Related to Outcomes in Patients with Acute Stroke. Journal of Clinical Medicine 9:2269.
1.
Tuñón J, Steg PG, Bhatt DL, Bittner VA, Díaz R, Goodman SG, Jukema JW, Kim Y-U, Li QH, Mueller C, Parkhomenko A, Pordy R, Sritara P, Szarek M, White HD, Zeiher AM, Schwartz GG, for the OOI. 2020. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. European Heart Journal 41:4114–4123.
1.
Tomaniak M, Chichareon P, Takahashi K, Kogame N, Modolo R, Chang CC, Spitzer E, Neumann F-J, Plante S, Hernández Antolin R, Jambrik Z, Gelev V, Brunel P, Konteva M, Beygui F, Morelle J-F, Filipiak KJ, Van Geuns R-J, Soliman O, Tijssen J, Rademaker-Havinga T, Storey RF, Hamm C, Steg PG, Windecker S, Onuma Y, Valgimigli M, Serruys PW, for the GLSI. 2020. Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. European Heart Journal - Cardiovascular Pharmacotherapy 6:222–230.
1.
Tomaniak M, Chichareon P, Modolo R, Takahashi K, Chang CC, Kogame N, Spitzer E, Buszman PE, Van Geuns R-JM, Valkov V, Steinwender C, Geisler T, Prokopczuk J, Sabaté M, Zmudka K, Rademaker-Havinga T, Tijssen JGP, Jüni P, Hamm C, Steg PG, Onuma Y, Vranckx P, Valgimigli M, Windecker S, Baber U, Anderson R, Dominici M, Serruys PW. 2020. Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. EuroIntervention 15:e1605–e1614.
1.
Thomalla G, Boutitie F, Ma H, Koga M, Ringleb P, Schwamm LH, Wu O, Bendszus M, Bladin CF, Campbell BCV, Cheng B, Churilov L, Ebinger M, Endres M, Fiebach JB, Fukuda-Doi M, Inoue M, Kleinig TJ, Latour LL, Lemmens R, Levi CR, Leys D, Miwa K, Molina CA, Muir KW, Nighoghossian N, Parsons MW, Pedraza S, Schellinger PD, Schwab S, Simonsen CZ, Song SS, Thijs V, Toni D, Hsu CY, Wahlgren N, Yamamoto H, Yassi N, Yoshimura S, Warach S, Hacke W, Toyoda K, Donnan GA, Davis SM, Gerloff C, Acosta BR, Aegidius K, Albiker C, Alegiani A, Almendrote M, Alonso A, Althaus K, Amarenco P, Amiri H, Anders B, Aniculaesei A, Appleton J, Arenillas J, Back C, Bähr C, Bardutzky J, Baronnet-Chauvet F, Bathe-Peters R, Bayer-Karpinska A, Becerra JL, Beck C, Belchí Guillamon O, Benoit A, Berhoune N, Bindila D, Birchenall J, Blanc-Lasserre K, Blanco Gonzales M, Bobinger T, Bodechtel U, Bodiguel E, Bojaryn U, Bonnet L, Bouamra B, Bourgeois P, Boutitie F, Breuer L, Breynaert L, Broughton D, Brouns R, Brugirard S, Bruneel B, Buggle F, Cakmak S, Calleja A, Calvet D, Carrera D, Chen H-C, Cheng B, Cheripelli B, Cho T-H, Choe C, Choy L, Christensen H, Ciatipis M, others. 2020. Intravenous alteplase for stroke with unknown time of onset guided by advanced imaging: systematic review and meta-analysis of individual patient data. The Lancet 396:1574–1584.
1.
Takahashi K, Wang R, Kawashima H, Tomaniak M, Gao C, Ono M, Hara H, Wykrzykowska JJ, De Winter RJ, Werner N, Teiger E, Almeida M, Barraud P, Lantelme P, Barlis P, Garg S, Hamm C, Steg PG, Onuma Y, Vranckx P, Windecker S, Valgimigli M, Serruys PW. 2020. Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial. International Journal of Cardiology 320:27–34.
1.
Takahashi K, Kogame N, Tomaniak M, Chichareon P, Chang C-C, Modolo R, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Van Geuns RJ, Dominici M, Huber K, Buszman P, Bolognese L, Tumscitz C, Żmudka K, Aminian A, Vrolix M, Petrov I, Wykrzykowska JJ, De Winter RJ, Hamm C, Steg PG, Onuma Y, Valgimigli M, Windecker S, Vranckx P, Garg S, Serruys PW. 2020. Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. Clinical Research in Cardiology 109:918–929.
1.
Takahashi K, Chichareon P, Modolo R, Kogame N, Chang CC, Tomaniak M, Moschovitis A, Curzen N, Haude M, Jung W, Holmvang L, Garg S, Tijssen JGP, Wykrzykowska JJ, De Winter RJ, Hamm C, Steg PG, Stoll H-P, Onuma Y, Valgimigli M, Vranckx P, Windecker S, Serruys PW. 2020. Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial. EuroIntervention 16:634–644.
1.
Ten Berg JM, Steg PG, Bhatt DL, Hohnloser SH, De Veer A, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Cannon CP. 2020. Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial). The American Journal of Cardiology 125:735–743.
1.
Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, Fras Z, Goodman SG, Halvorsen S, Harrington RA, Jukema JW, Moriarty PM, Pordy R, Ray KK, Sinnaeve P, Tsimikas S, Vogel R, White HD, Zahger D, Zeiher AM, Steg PG, Schwartz GG, for the OOI. 2020. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. European Heart Journal 41:4245–4255.
1.
Steg PG, Ducrocq G, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP. 2020. Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation. Journal of the American College of Cardiology 75:238–240.
1.
Spertus JA, Jones PG, Maron DJ, Mark DB, O’Brien SM, Fleg JL, Reynolds HR, Stone GW, Sidhu MS, Chaitman BR, Chertow GM, Hochman JS, Bangalore S. 2020. Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. New England Journal of Medicine 382:1619–1628.
1.
Sorrentino S, Sartori S, Baber U, Claessen BE, Giustino G, Chandrasekhar J, Chandiramani R, Cohen DJ, Henry TD, Guedeney P, Ariti C, Dangas G, Gibson CM, Krucoff MW, Moliterno DJ, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Urban P, Mehran R. 2020. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. Circulation: Cardiovascular Interventions 13:e008226.
1.
Stavres J, Luck JC, Ducrocq GP, Cauffman AE, Pai S, Sinoway LI. 2020. Central and peripheral modulation of exercise pressor reflex sensitivity after nonfatiguing work. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 319:R575–R583.
1.
Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Lu W, Spiro TE, Barnathan ES, Raskob GE. 2020. Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. Journal of the American College of Cardiology 75:3140–3147.
1.
Sorbets E, Steg PG. 2020. Direct-acting Anticoagulants in Chronic Coronary Syndromes. European Cardiology Review 15:e10.
1.
Sinnaeve PR, Schwartz GG, Wojdyla DM, Alings M, Bhatt DL, Bittner VA, Chiang C-E, Correa Flores RM, Diaz R, Dorobantu M, Goodman SG, Jukema JW, Kim Y-U, Pordy R, Roe MT, Sy RG, Szarek M, White HD, Zeiher AM, Steg PG, for the OOI. 2020. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. European Heart Journal 41:2248–2258.
1.
Silvain J, Lattuca B, Beygui F, Rangé G, Motovska Z, Dillinger J-G, Boueri Z, Brunel P, Lhermusier T, Pouillot C, Larrieu-Ardilouze E, Boccara F, Labeque J-N, Guedeney P, El Kasty M, Laredo M, Dumaine R, Ducrocq G, Collet J-P, Cayla G, Blanchart K, Kala P, Vicaut E, Montalescot G, Silvain J, Collet J-P, Montalescot G, Kerneis M, Braik N, Barthelemy O, Helft G, Lefeuvre C, Choussat R, Hauguel M, Zeitouni M, Cuisset T, Bonnet J-L, Deharo P, Lattuca B, Cayla G, Cornillet L, Ledermann B, Lonjon C, Schmutz L, Range G, Albert F, Demicheli T, Roussel L, Bensaid R, Thuaire C, Dillinger J-G, Henry P, Manzo-Silberman S, Sideris G, Logeart D, Spagnoli V, Cacoub L, Pouillot C, Vi-Fane JR, Glasenapp J, Bougrini K, Combaret N, Motreff P, Souteyrand G, Amonchot A, Mouyen T, Lhermusier T, Carrie D, Bouisset F, Chollet T, Campelo-Parada F, Delarche N, Schiele F, Besutti M, Hauguel-Moreau M, El Mahmoud R, Caussin C, Zoheir M, Veugeois A, Dibie A, Varenne O, Picard F, Lafont A, Adjedj J, Degrell P, Beygui F, Sabatier R, Roule V, Bignon M, Blanchart K, Ardouin P, Lemaitre A, Briet C, Boueri Z, Goube P, Coste P, Cetran L, Clerc J, Le Breton H, Boulmier D, others. 2020. Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial. The Lancet 396:1737–1744.
1.
Sorbets E, Fox KM, Elbez Y, Danchin N, Dorian P, Ferrari R, Ford I, Greenlaw N, Kalra PR, Parma Z, Shalnova S, Tardif J-C, Tendera M, Zamorano JL, Vidal-Petiot E, Steg PG, investigators C. 2020. Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. European Heart Journal 41:347–356.
1.
Silvain J, Cayla G, Beygui F, Range G, Lattuca B, Collet J-P, Dillinger J-G, Boueri Z, Brunel P, Pouillot C, Boccara F, Christiaens L, Labeque J-N, Lhermusier T, Georges J-L, Bellemain-Appaix A, Le Breton H, Hauguel-Moreau M, Saint-Etienne C, Caussin C, Jourda F, Motovska Z, Guedeney P, El Kasty M, Laredo M, Dumaine R, Ducrocq G, Vicaut E, Montalescot G. 2020. Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study. American Heart Journal 225:27–37.
1.
Sheth T, Pinilla-Echeverri N, Moreno R, Wang J, Wood DA, Storey RF, Mehran R, Bainey KR, Bossard M, Bangalore S, Schwalm J-D, Velianou JL, Valettas N, Sibbald M, Rodés-Cabau J, Ducas J, Cohen EA, Bagai A, Rinfret S, Newby DE, Feldman L, Laster SB, Lang IM, Mills JD, Cairns JA, Mehta SR. 2020. Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease. Journal of the American College of Cardiology 76:1277–1286.
1.
Schwartz GG, Szarek M, Bittner VA, Steg PG. 2020. Response by Schwartz et al to Letter Regarding Article, “Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.” Circulation 142.
1.
Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, Kim Y-U, Jukema JW, Pordy R, Roe MT, White HD, Bhatt DL, For the OOC, Investigators*. 2020. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation 141:1608–1617.
1.
Schiele F, Lemesle G, Angoulvant D, Krempf M, Kownator S, Cheggour S, Belle L, Ferrières J, Bauters C, Bergerot C, Beygui F, Boccara F, Bonnefoy E, Bruckert E, Cayla G, Collet J-P, Coste P, Descotes-Genon V, Ducrocq G, Elbaz M, Farnier M, Ferrari E, Guedj D, Levai L, Mansourati J, Mansencal N, Meneveau N, Meune C, Morel O, Ohlmann P, Paillard F, Piot C, Puymirat E, Rioufol G, Roubille F, Sabouret P, Teiger E. 2020. Proposal for a standardized discharge letter after hospital stay for acute myocardial infarction. European Heart Journal Acute Cardiovascular Care 9:788–801.
1.
Sabatine MS, Hiatt WR, Goto S, Johnston SC, Bonaca MP, Steg PG, Bhatt DL, Cannon CP, Andersson M, Wallentin L. 2020. No Significant Relationship Between Ticagrelor and Sleep Apnea in Large, Randomized, Blinded Trials. JACC: Cardiovascular Interventions 13:1012–1014.
1.
Puymirat E, Simon T, De Bruyne B, Montalescot G, Steg G, Cayla G, Durand-Zaleski I, Blanchard D, Danchin N, Chatellier G. 2020. Rationale and design of the Flow Evaluation to Guide Revascularization in Multivessel ST-Elevation Myocardial Infarction (FLOWER-MI) trial. American Heart Journal 222:1–7.
1.
Pico F, Lapergue B, Ferrigno M, Rosso C, Meseguer E, Chadenat M-L, Bourdain F, Obadia M, Hirel C, Duong DL, Deltour S, Aegerter P, Labreuche J, Cattenoy A, Smadja D, Hosseini H, Guillon B, Wolff V, Samson Y, Cordonnier C, Amarenco P. 2020. Effect of In-Hospital Remote Ischemic Perconditioning on Brain Infarction Growth and Clinical Outcomes in Patients With Acute Ischemic Stroke: The RESCUE BRAIN Randomized Clinical Trial. JAMA Neurology 77:725.
1.
Parma Z, Jasilek A, Greenlaw N, Ferrari R, Ford I, Fox K, Tardif J, Tendera M, Steg PG. 2020. Incident heart failure in outpatients with chronic coronary syndrome: results from the international prospective CLARIFY registry. European Journal of Heart Failure 22:804–812.
1.
Ozen G, Benyahia C, Mani S, Boukais K, Silverstein AM, Bayles R, Nelsen AC, Castier Y, Danel C, Mal H, Clapp LH, Longrois D, Norel X. 2020. Bronchodilation induced by PGE2 is impaired in Group III pulmonary hypertension. British Journal of Pharmacology 177:161–174.
1.
Ozen G, Benyahia C, Amgoud Y, Patel J, Abdelazeem H, Bouhadoun A, Yung S, Li F, Mahieddine Y, Silverstein AM, Castier Y, Cazes A, Longrois D, Clapp LH, Norel X. 2020. Interaction between PGI2 and ET-1 pathways in vascular smooth muscle from Group-III pulmonary hypertension patients. Prostaglandins & Other Lipid Mediators 146:106388.
1.
Ozen G, Amgoud Y, Abdelazeem H, Mani S, Benyahia C, Bouhadoun A, Tran-Dinh A, Castier Y, Guyard A, Longrois D, Silverstein AM, Norel X. 2020. Downregulation of PGI2 pathway in Pulmonary Hypertension Group-III patients. Prostaglandins, Leukotrienes and Essential Fatty Acids 160:102158.
1.
Ozen G, Aljesri K, Celik Z, Turkyılmaz G, Turkyılmaz S, Teskin O, Norel X, Topal G. 2020. Mechanism of thromboxane receptor-induced vasoconstriction in human saphenous vein. Prostaglandins & Other Lipid Mediators 151:106476.
1.
Ono M, Chichareon P, Tomaniak M, Kawashima H, Takahashi K, Kogame N, Modolo R, Hara H, Gao C, Wang R, Walsh S, Suryapranata H, Da Silva PC, Cotton J, Koning R, Akin I, Rensing BJWM, Garg S, Wykrzykowska JJ, Piek JJ, Jüni P, Hamm C, Steg PG, Valgimigli M, Windecker S, Storey RF, Onuma Y, Vranckx P, Serruys PW. 2020. The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. Clinical Research in Cardiology 109:1125–1139.
1.
Ong E, Meseguer E, Guidoux C, Lavallée PC, Hobeanu C, Charles H, Labreuche J, Cabrejo L, Martin-Bechet A, Rigual R, Nighoghossian N, Amarenco P. 2020. Prevalence and Outcome of Potential Candidates for Left Atrial Appendage Closure After Stroke With Atrial Fibrillation: WATCH-AF Registry. Stroke 51:2355–2363.
1.
Norel X, Sugimoto Y, Ozen G, Abdelazeem H, Amgoud Y, Bouhadoun A, Bassiouni W, Goepp M, Mani S, Manikpurage HD, Senbel A, Longrois D, Heinemann A, Yao C, Clapp LH. 2020. International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E2 Receptors (EP1–4) and Prostacyclin Receptor (IP): Specific Roles in Pathophysiologic Conditions. Pharmacological Reviews 72:910–968.
1.
Nicolau JC, Bhatt DL, Hohnloser SH, Kimura T, Lip GYH, Miede C, Nordaby M, Oldgren J, Steg PG, Ten Berg JM, Godoy LC, Cannon CP, The REDPCISC, Investigators. 2020. Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial. Drugs 80:995–1005.
1.
Mesnier J, Cottin Y, Coste P, Ferrari E, Schiele F, Lemesle G, Thuaire C, Angoulvant D, Cayla G, Bouleti C, Gallet De Saint Aurin R, Goube P, Lhermusier T, Dillinger J-G, Paganelli F, Saib A, Prunier F, Vanzetto G, Dubreuil O, Puymirat E, Boccara F, Eltchaninoff H, Cachanado M, Rousseau A, Drouet E, Steg P-G, Simon T, Danchin N. 2020. Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in France: a registry study. The Lancet Public Health 5:e536–e542.
1.
Mesnier J, Cottin Y, Coste P, Ferrari E, Schiele F, Lemesle G, Thuaire C, Angoulvant D, Cayla G, Bouleti C, De Saint Aurin RG, Goube P, Lhermusier T, Dillinger J-G, Paganelli F, Saib A, Prunier F, Vanzetto G, Dubreuil O, Puymirat E, Boccara F, Eltchaninoff H, Cachanado M, Rousseau A, Drouet E, Steg G, Simon T, Danchin N. 2020. Hospital Admissions for Acute Myocardial Infarction Before and After Lockdown According to Regional Prevalence of COVID-19 and Patient Profile. SSRN Electronic Journal https://doi.org/10.2139/ssrn.3619808.
1.
Mesnier J, Collet JP. 2020. Vascular Access Site for TAVR. JACC: Cardiovascular Interventions 13:1469–1470.
1.
Meseguer E, Diallo D, Labreuche J, Charles H, Delbosc S, Mangin G, Monteiro Tavares L, Caligiuri G, Nicoletti A, Amarenco P. 2020. Osteopontin Predicts Three-Month Outcome in Stroke Patients Treated by Reperfusion Therapies. Journal of Clinical Medicine 9:4028.
1.
Marquis-Gravel G, Huang Z, Zelenkofske SL, Lincoff AM, Mehran R, Steg PG, Bode C, Alexander JH, Povsic TJ. 2020. Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial. American Heart Journal 223:84–86.
1.
Marquis-Gravel G, Dalgaard F, Jones AD, Lokhnygina Y, James SK, Harrington RA, Wallentin L, Steg PG, Lopes RD, Storey RF, Goodman SG, Mahaffey KW, Tricoci P, White HD, Armstrong PW, Ohman EM, Alexander JH, Roe MT. 2020. Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. Journal of the American College of Cardiology 76:162–171.
1.
Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O’Brien SM, Boden WE, Chaitman BR, Senior R, López-Sendón J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamaz A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE, Rockhold FW, Broderick S, Ferguson TB, Williams DO, Harrington RA, Stone GW, Rosenberg Y. 2020. Initial Invasive or Conservative Strategy for Stable Coronary Disease. New England Journal of Medicine 382:1395–1407.
1.
Marston NA, Bonaca MP, Jarolim P, Goodrich EL, Bhatt DL, Steg PG, Cohen M, Storey RF, Johanson P, Wiviott SD, Braunwald E, Sabatine MS, Morrow DA. 2020. Clinical Application of High-Sensitivity Troponin Testing in the Atherosclerotic Cardiovascular Disease Framework of the Current Cholesterol Guidelines. JAMA Cardiology 5:1255.
1.
Lim A, Singhal S, Lavallee P, Amarenco P, Rothwell PM, Albers G, Sharma M, Brown R, Ranta A, Maddula M, Kleinig T, Dawson J, Elkind MSV, Guarino M, Coutts SB, Clissold B, Ma H, Phan T. 2020. An International Report on the Adaptations of Rapid Transient Ischaemic Attack Pathways During the COVID-19 Pandemic. Journal of Stroke and Cerebrovascular Diseases 29:105228.
1.
Li L, Luengo-Fernandez R, Zuurbier SM, Beddows NC, Lavallee P, Silver LE, Kuker W, Rothwell PM. 2020. Ten-year risks of recurrent stroke, disability, dementia and cost in relation to site of primary intracerebral haemorrhage: population-based study. Journal of Neurology, Neurosurgery & Psychiatry 91:580–585.

2019

1.
Zelniker TA, Morrow DA, Mosenzon O, Gurmu Y, Im K, Cahn A, Raz I, Steg PG, Leiter LA, Braunwald E, Bhatt DL, Scirica BM. 2019. Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53. Clinical Chemistry 65:781–790.
1.
Yong CM, Sundaram V, Abnousi F, Olivier CB, Yang J, Stone GW, Steg PG, Michael Gibson C, Hamm CW, Price MJ, Deliargyris EN, Prats J, White HD, Harrington RA, Bhatt DL, Mahaffey KW, on behalf of the CPI. 2019. The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. Clinical Cardiology 42:797–805.
1.
White HD, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Erglis A, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lopes RD, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Sritara P, Tricoci P, Zeiher AM, Schwartz GG, Investigators OO. 2019. Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial. European Heart Journal 40:2801–2809.
1.
Yeh RW, Kereiakes DJ, Secemsky EA, Steg PG, Mauri L. 2019. The DAPT Score in Sweden. Journal of the American College of Cardiology 73:113–114.
1.
Vogel B, Claessen BE, Arnold SV, Chan D, Cohen DJ, Giannitsis E, Gibson CM, Goto S, Katus HA, Kerneis M, Kimura T, Kunadian V, Pinto DS, Shiomi H, Spertus JA, Steg PG, Mehran R. 2019. ST-segment elevation myocardial infarction. Nature Reviews Disease Primers 5:39.
1.
Vogel B, Chandrasekhar J, Baber U, Mastoris I, Sartori S, Aquino M, Krucoff MW, Moliterno DJ, Henry TD, Weisz G, Gibson CM, Iakovou I, Kini AS, Farhan S, Sorrentino S, Faggioni M, Colombo A, Steg PG, Witzenbichler B, Chieffo A, Cohen DJ, Stuckey T, Ariti C, Dangas GD, Pocock S, Mehran R. 2019. Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thrombosis and Haemostasis 119:1704–1711.
1.
Vidal-Petiot E, Greenlaw N, Kalra PR, Garcia-Moll X, Tardif J-C, Ford I, Zamorano J, Ferrari R, Tendera M, Fox KM, Steg PG, on behalf of the C investigators. 2019. Chronic Kidney Disease Has a Graded Association with Death and Cardiovascular Outcomes in Stable Coronary Artery Disease: An Analysis of 21,911 Patients from the CLARIFY Registry. Journal of Clinical Medicine 9:4.
1.
Valgimigli M, Garcia-Garcia HM, Vrijens B, Vranckx P, McFadden EP, Costa F, Pieper K, Vock DM, Zhang M, Van Es G-A, Tricoci P, Baber U, Steg G, Montalescot G, Angiolillo DJ, Serruys PW, Farb A, Windecker S, Kastrati A, Colombo A, Feres F, Jüni P, Stone GW, Bhatt DL, Mehran R, Tijssen JGP. 2019. Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). European Heart Journal 40:2070–2085.
1.
Tomaniak M, Chichareon P, Onuma Y, Deliargyris EN, Takahashi K, Kogame N, Modolo R, Chang CC, Rademaker-Havinga T, Storey RF, Dangas GD, Bhatt DL, Angiolillo DJ, Hamm C, Valgimigli M, Windecker S, Steg PG, Vranckx P, Serruys PW, for the GLTI. 2019. Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial. JAMA Cardiology 4:1092.
1.
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Group ESCSD, Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, Mickley H, Crea F, Van De Werf F, Bucciarelli-Ducci C, Katus HA, Pinto FJ, Antman EM, Hamm CW, De Caterina R, Januzzi JL, Apple FS, Alonso Garcia MA, Underwood SR, Canty JM, Lyon AR, Devereaux PJ, Zamorano JL, Lindahl B, Weintraub WS, Newby LK, Virmani R, Vranckx P, Cutlip D, Gibbons RJ, Smith SC, Atar D, Luepker RV, Robertson RM, Bonow RO, Steg PG, O’Gara PT, Fox KAA, Hasdai D, Aboyans V, Achenbach S, Agewall S, Alexander T, Avezum A, Barbato E, Bassand J-P, Bates E, Bittl JA, Breithardt G, Bueno H, Bugiardini R, Cohen MG, Dangas G, De Lemos JA, Delgado V, Filippatos G, Fry E, Granger CB, Halvorsen S, Hlatky MA, Ibanez B, James S, Kastrati A, Leclercq C, Mahaffey KW, Mehta L, Müller C, Patrono C, Piepoli MF, Piñeiro D, Roffi M, Rubboli A, Sharma S, Simpson IA, Tendera M, Valgimigli M, Van Der Wal AC, Windecker S, Chettibi M, Hayrapetyan H, Roithinger FX, Aliyev F, Sujayeva V, Claeys MJ, Smajić E, Kala P, Iversen KK, El Hefny E, Marandi T, Porela P, Antov S, others. 2019. Fourth universal definition of myocardial infarction (2018). European Heart Journal 40:237–269.
1.
the PI, Åkerblom A, Wojdyla D, Steg PG, Wallentin L, James SK, Budaj A, Katus HA, Himmelmann A, Huber K, Siegbahn A, Storey RF, Becker RC. 2019. Prevalence and relevance of abnormal glucose metabolism in acute coronary syndromes: insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. Journal of Thrombosis and Thrombolysis 48:563–569.
1.
Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chiang C-E, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Kimura T, Kiss RG, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Tricoci P, Xavier D, Zeiher AM, Steg PG. 2019. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events. Journal of the American College of Cardiology 73:387–396.
1.
Ten Berg JM, De Veer A, Oldgren J, Steg PG, Zateyshchikov DA, Jansky P, Seung K-B, Hohnloser SH, Lip GYH, Nordaby M, Kleine E, Bhatt DL, Cannon CP. 2019. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation. JACC: Cardiovascular Interventions 12:2331–2341.
1.
Tan NS, Sarak B, Fox KA, Brieger D, Steg PG, Gale CP, Bhatt DL, Spencer FA, Grondin FR, Goodman SG, Yan AT, on behalf of the Canadian GG, Investigators C. 2019. Pulse pressure in acute coronary syndromes: Comparative prognostic significance with systolic blood pressure. European Heart Journal: Acute Cardiovascular Care 8:309–317.
1.
Takahashi K, Serruys PW, Chichareon P, Chang CC, Tomaniak M, Modolo R, Kogame N, Magro M, Chowdhary S, Eitel I, Zweiker R, Ong P, Ottesen MM, Tijssen JGP, Wykrzykowska JJ, De Winter RJ, Garg S, Stoll H-P, Hamm C, Steg PG, Onuma Y, Valgimigli M, Vranckx P, Carrie D, Windecker S. 2019. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. Journal of the American College of Cardiology 74:2015–2027.
1.
Szarek M, Steg PG, DiCenso D, Bhatt DL, Bittner VA, Budaj A, Diaz R, Goodman SG, Gotcheva N, Jukema JW, Pordy R, Roe MT, Sourdille T, White HD, Xavier D, Zeiher AM, Schwartz GG, for the OOC, Investigators*. 2019. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. Circulation: Cardiovascular Quality and Outcomes 12:e005858.
1.
Stone GW, Kappetein AP, Sabik JF, Pocock SJ, Morice M-C, Puskas J, Kandzari DE, Karmpaliotis D, Brown WM, Lembo NJ, Banning A, Merkely B, Horkay F, Boonstra PW, Van Boven AJ, Ungi I, Bogáts G, Mansour S, Noiseux N, Sabaté M, Pomar J, Hickey M, Gershlick A, Buszman PE, Bochenek A, Schampaert E, Pagé P, Modolo R, Gregson J, Simonton CA, Mehran R, Kosmidou I, Généreux P, Crowley A, Dressler O, Serruys PW. 2019. Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. New England Journal of Medicine 381:1820–1830.
1.
Steg PG, Szarek M, Bhatt DL, Bittner VA, Brégeault M-F, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Ostadal P, Parkhomenko A, Pordy R, Roe MT, Tricoci P, Vogel R, White HD, Zeiher AM, Schwartz GG, For the OOC, Investigators†. 2019. Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. Circulation 140:103–112.
1.
Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstråle W, Leonsson-Zachrisson M, Liu Y, Opolski G, Zateyshchikov D, Ge J, Nicolau JC, Corbalán R, Cornel JH, Widimský P, Leiter LA. 2019. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. New England Journal of Medicine 381:1309–1320.
1.
Stefanescu Schmidt AC, Steg PG, Yeh RW, Kereiakes DJ, Tanguay J-F, Hsieh W-H, Massaro JM, Mauri L, Cutlip DE. 2019. Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study). The American Journal of Cardiology 124:1813–1820.
1.
Sorbets E, Steg PG, Young R, Danchin N, Greenlaw N, Ford I, Tendera M, Ferrari R, Merkely B, Parkhomenko A, Reid C, Tardif J-C, Fox KM, for the C investigators. 2019. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. European Heart Journal 40:1399–1407.
1.
Si S, Golledge J, Norman P, Nelson M, Chew D, Ademi Z, Bhatt DL, Steg GP, Reid CM. 2019. Prevalence and Outcomes of Undiagnosed Peripheral Arterial Disease Among High Risk Patients in Australia: An Australian REACH Sub-Study. Heart, Lung and Circulation 28:939–945.
1.
Shen L, Patel JA, Norel X, Moledina S, Whittle BJ, Von Kessler K, Sista P, Clapp LH. 2019. Pharmacology of the single isomer, esuberaprost (beraprost-314d) on pulmonary vascular tone, IP receptors and human smooth muscle proliferation in pulmonary hypertension. Biochemical Pharmacology 166:242–252.
1.
Serruys PW, Takahashi K, Chichareon P, Kogame N, Tomaniak M, Modolo R, Chang CC, Komiyama H, Soliman O, Wykrzykowska JJ, De Winter RJ, Ferrario M, Dominici M, Buszman P, Bolognese L, Tumscitz C, Benit E, Stoll H-P, Hamm C, Steg PG, Onuma Y, Jüni P, Windecker S, Vranckx P, Colombo A, Valgimigli M. 2019. Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. European Heart Journal 40:2595–2604.
1.
Serruys PW, Tomaniak M, Chichareon P, Modolo R, Kogame N, Takahashi K, Chang CC, Spitzer E, Walsh SJ, Adlam D, Hildick-Smith D, Édes I, Van De Harst P, Krackhardt F, Tijssen JGP, Rademaker-Havinga T, Garg S, Steg PG, Hamm C, Jüni P, Vranckx P, Onuma Y, Verheugt FWA. 2019. Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial. EuroIntervention 15:e1090–e1098.
1.
Schiele F, Puymirat E, Ferrières J, Simon T, Fox KAA, Eikelboom J, Danchin N. 2019. The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population. International Journal of Cardiology 278:7–13.
1.
Schoos M, Power D, Baber U, Sartori S, Claessen B, Camaj A, Steg P, Ariti C, Weisz G, Witzenbichler B, Henry T, Cohen D, Antoniucci D, Krucoff M, Hermiller J, Gibson C, Chieffo A, Moliterno D, Colombo A, Pocock S, Dangas G, Mehran R. 2019. Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. The American Journal of Cardiology 123:709–716.
1.
Roe MT, Li QH, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Lopez-Jaramillo P, Lopes RD, Louie MJ, Moriarty PM, Szarek M, Vogel R, White HD, Zeiher AM, Baccara-Dinet MT, Steg PG, Schwartz GG, For the OOI. 2019. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Circulation 140:1578–1589.
1.
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG, Schwartz GG, Steg PG, Bhatt DL, Bittner VA, Diaz R, Goodman SG, Harrington RA, Jukema JW, Szarek M, White HD, Zeiher AM, Tricoci P, Roe MT, Mahaffey KW, Edelberg JM, Hanotin C, Lecorps G, Moryusef A, Pordy R, Sasiela WJ, Tamby J-F, Aylward PE, Drexel H, Sinnaeve P, Dilic M, Lopes RD, Gotcheva NN, Prieto J-C, Yong H, López-Jaramillo P, Pećin I, Reiner Z, Ostadal P, Viigimaa M, Nieminen MS, Chumburidze V, Marx N, Danchin N, Liberopoulos E, Montenegro Valdovinos PC, Tse H-F, Kiss RG, Xavier D, Zahger D, Valgimigli M, Kimura T, Kim HS, Kim S-H, Erglis A, Laucevicius A, Kedev S, Yusoff K, Ramos López GA, Alings M, Halvorsen S, Correa Flores RM, Budaj A, Morais J, Dorobantu M, Karpov Y, Ristic AD, Chua T, Murin J, Fras Z, Dalby AJ, Tuñón J, De Silva HA, Hagström E, Landmesser U, Chiang C-E, Sritara P, Guneri S, Parkhomenko A, Ray KK, Moriarty PM, Vogel R, others. 2019. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. The Lancet Diabetes & Endocrinology 7:618–628.
1.
Povsic TJ, Ohman EM, Roe MT, White J, Rockhold FW, Montalescot G, Cornel JH, Nicolau JC, Steg PG, James S, Bode C, Welsh RC, Plotnikov AN, Mundl H, Gibson CM. 2019. P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. JAMA Cardiology 4:680.
1.
Puymirat E, Bonaca M, Iliou M-C, Tea V, Ducrocq G, Douard H, Labrunee M, Plastaras P, Chevallereau P, Taldir G, Bataille V, Ferrières J, Schiele F, Simon T, Danchin N. 2019. Outcome associated with prescription of cardiac rehabilitation according to predicted risk after acute myocardial infarction: Insights from the FAST-MI registries. Archives of Cardiovascular Diseases 112:459–468.
1.
Puymirat E, Bonaca M, Fumery M, Tea V, Aissaoui N, Lemesles G, Bonello L, Ducrocq G, Cayla G, Ferrières J, Schiele F, Simon T, Danchin N, for the F investigators. 2019. Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non‐ST Elevation Myocardial Infarction registries. Clinical Cardiology 42:227–234.
1.
Picard F, Bhatt DL, Ducrocq G, Elbez Y, Ferrari R, Ford I, Tardif J-C, Tendera M, Fox KM, Steg PG. 2019. Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease. Journal of the American College of Cardiology 73:1362–1364.
1.
Picard F, Van Ganse E, Ducrocq G, Danchin N, Falissard B, Hanon O, Belhassen M, Ginoux M, Lefevre C, Cotte F, Mahé I, Steg PG. 2019. Evaluatio N of A pi X aban in str O ke and systemic embolism prevention in patients with non‐valvular atrial fibrillation in clinical practice S etting in France, rationale and design of the NAXOS: SNIIRAM study. Clinical Cardiology 42:851–859.
1.
Parma Z, Young R, Roleder T, Marona M, Ford I, Tendera M, Steg PG, Stępińska J. 2019. Management strategies and 5-year outcomes in Polish patients with stable coronary artery disease in the CLARIFY registry versus other European countries. Polish Archives of Internal Medicine https://doi.org/10.20452/pamw.14789.
1.
Palmerini T, Bruno AG, Gilard M, Morice M-C, Valgimigli M, Montalescot G, Collet J-P, Della Riva D, Bacchi-Reggiani ML, Steg PG, Diallo A, Vicaut E, Helft G, Nakamura M, Généreux P, Vahl TP, Stone GW. 2019. Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation: A Pairwise Meta-Analysis of 6 Trials and 21 457 Patients. Circulation: Cardiovascular Interventions 12:e007541.
1.
Ozen G, Boumiza S, Deschildre C, Topal G, Longrois D, Jakobsson P, Michel J, Jacob M, Chahed K, Norel X. 2019. Inflammation increases MMP levels via PGE2 in human vascular wall and plasma of obese women. International Journal of Obesity 43:1724–1734.
1.
Olivier CB, Bhatt DL, Leonardi S, Stone GW, Gibson CM, Steg PG, Hamm CW, Wilson MD, Mangum S, Price MJ, Prats J, White HD, Lopes RD, Harrington RA, Mahaffey KW, on Behalf of the CPI. 2019. Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention: Results From CHAMPION PHOENIX. Circulation: Cardiovascular Interventions 12:e007342.
1.
Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Brueckmann M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP. 2019. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. European Heart Journal 40:1553–1562.
1.
Ntaios G, Swaminathan B, Berkowitz SD, Gagliardi RJ, Lang W, Siegler JE, Lavados P, Mundl H, Bornstein N, Meseguer E, Amarenco P, Cucchiara B, Camps-Renom P, Makaritsis K, Korompoki E, Papavasileiou V, Marti-Fabregas J, Milionis H, Vemmos K, Connolly SJ, Hart RG, on behalf of the NEI. 2019. Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. Stroke 50:2477–2485.
1.
Ntaios G, Pearce LA, Meseguer E, Endres M, Amarenco P, Ozturk S, Lang W, Bornstein NM, Molina CA, Pagola J, Mundl H, Berkowitz SD, Liu YY, Sen S, Connolly SJ, Hart RG, on behalf of the NEI. 2019. Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial. Stroke 50:3184–3190.
1.
Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O’Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Cook Bruns N, Muehlhofer E, Dagenais GR, Kim J-H, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar A, Parkhomenko AN, Ryden L, Pogosova N, Dans A, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik T, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne K, Fox KAA, Yusuf S. 2019. Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology 157:403-412.e5.
1.
Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O’Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim J-H, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S. 2019. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology 157:682-691.e2.
1.
Mehta SR, Wood DA, Storey RF, Mehran R, Bainey KR, Nguyen H, Meeks B, Di Pasquale G, López-Sendón J, Faxon DP, Mauri L, Rao SV, Feldman L, Steg PG, Avezum Á, Sheth T, Pinilla-Echeverri N, Moreno R, Campo G, Wrigley B, Kedev S, Sutton A, Oliver R, Rodés-Cabau J, Stanković G, Welsh R, Lavi S, Cantor WJ, Wang J, Nakamya J, Bangdiwala SI, Cairns JA. 2019. Complete Revascularization with Multivessel PCI for Myocardial Infarction. New England Journal of Medicine 381:1411–1421.
1.
Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, Džavík V, Escaned J, Gil R, Gurbel P, Hamm CW, Henry T, Huber K, Kastrati A, Kaul U, Kornowski R, Krucoff M, Kunadian V, Marx SO, Mehta SR, Moliterno D, Ohman EM, Oldroyd K, Sardella G, Sartori S, Shlofmitz R, Steg PG, Weisz G, Witzenbichler B, Han Y, Pocock S, Gibson CM. 2019. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. New England Journal of Medicine 381:2032–2042.
1.
Maeng M, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GYH, Oldgren J, Ten Berg JM, Cannon CP. 2019. Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post–PCI in Patients With Atrial Fibrillation and Diabetes. JACC: Cardiovascular Interventions 12:2346–2355.
1.
Lip GYH, Mauri L, Montalescot G, Ozkor M, Vardas P, Steg PG, Bhatt DL, Hohnloser SH, Miede C, Nordaby M, Brueckmann M, Kreuzer J, Kimura T, Oldgren J, Ten Berg JM, Cannon CP. 2019. Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. American Heart Journal 212:13–22.
1.
Lip GYH, Bhatt DL, Hohnloser SH, Kimura T, Miede C, Nordaby M, Oldgren J, Steg PG, Ten Berg JM, Cannon CP. 2019. Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation Post-PCI. Journal of the American College of Cardiology 74:2431–2433.
1.
Leonardi S, Franzone A, Piccolo R, McFadden E, Vranckx P, Serruys P, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Van Geuns R-J, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Steg G, Heg D, Juni P, Windecker S, Valgimigli M. 2019. Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY). BMJ Open 9:e026053.

2018

1.
Zeng X, Lincoff AM, Schulz-Schüpke S, Steg PG, Elbez Y, Mehran R, Stone GW, McAndrew T, Lin J, Zhang X, Shi W, Lei H, Jing Z, Huang W. 2018. Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: Meta-analysis. Journal of Cardiology 71:494–504.
1.
Worme MD, Tan MK, Armstrong DWJ, Yan AT, Tan NS, Brieger D, Budaj A, Gore JM, López-Sendón J, Van De Werf F, Steg PG, Fox KAA, Goodman SG, Udell JA. 2018. Previous and New Onset Atrial Fibrillation and Associated Outcomes in Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events). The American Journal of Cardiology 122:944–951.
1.
Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, Van Es GA, McFadden EP, Onuma Y, Van Meijeren C, Chichareon P, Benit E, Möllmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, Windecker S, Abdellaoui M, Adlam D, Akin I, Albarran Gonzalez-Trevilla A, Almeida M, Alves Lemos Neto P, Aminian A, Anderson R, Andreae R, Angioi M, Asano T, Barbato E, Barlis P, Barraud P, Benit E, Bertrand O, Beygui F, Bolognese L, Botelho R, Bouwman C, Bressers M, Brunel P, Buszman P, Buysschaert I, Canas Da Silva P, Carrie D, Cequier A, Chichareon P, Chin Chang C, Chowdhary S, Collet C, Colombo A, Cotton J, Cruz Ferreira R, Curello S, Curzen N, De Bot J, De Vreede T, Delle Karth G, Dijksma L, Dominici M, Édes I, Eeckhout E, Eitel I, Faluközy J, Fath-Ordoubadi F, Ferrario M, Fontos G, Francisco Diaz J, Freitas Quintella E, Frey B, Friedrich G, Galasko G, Galuszka G, Gama Ribeiro V, Garg S, Gargiulo G, Geisler T, Gelev V, Ghandilyan A, Goicolea J, Gori T, Gragnano F, Guimarães A, Hamm C, Haude M, Heg D, Heijke P, Hernández Antolin RA, Hildick-Smith D, Hillen D, Hoekman I, Hofma S, Holmvang L, Hoole S, Horváth I, Huber K, others. 2018. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. The Lancet 392:940–949.
1.
Villeret B, Dieu A, Straube M, Solhonne B, Miklavc P, Hamadi S, Le Borgne R, Mailleux A, Norel X, Aerts J, Diallo D, Rouzet F, Dietl P, Sallenave J-M, Garcia-Verdugo I. 2018. Silver Nanoparticles Impair Retinoic Acid-Inducible Gene I-Mediated Mitochondrial Antiviral Immunity by Blocking the Autophagic Flux in Lung Epithelial Cells. ACS Nano 12:1188–1202.
1.
Vidal-Petiot E, Sorbets E, Bhatt DL, Ducrocq G, Elbez Y, Ferrari R, Ford I, Tardif J-C, Tendera M, Fox KM, Steg PG. 2018. Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry. European Heart Journal 39:3855–3863.
1.
Vidal-Petiot E, Greenlaw N, Ford I, Ferrari R, Fox KM, Tardif J-C, Tendera M, Parkhomenko A, Bhatt DL, Steg PG, for the CI. 2018. Relationships Between Components of Blood Pressure and Cardiovascular Events in Patients with Stable Coronary Artery Disease and Hypertension. Hypertension 71:168–176.
1.
Vidal-Petiot E, Joseph A, Resche-Rigon M, Boutten A, Mullaert J, D’ Ortho M-P, Vrtovsnik F, Steg PG, Flamant M. 2018. External validation and comparison of formulae estimating 24-h sodium intake from a fasting morning urine sample. Journal of Hypertension 36:785–792.
1.
Vidal-Petiot E, Elbez Y, Lüscher TF, Fox KM, Steg PG. 2018. The 2018 ESC-ESH guidelines for the management of arterial hypertension leave clinicians facing a dilemma in half of the patients. European Heart Journal 39:4040–4041.
1.
Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann F-J, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN, Group ESCSD, Badimon L, Vranckx P, Agewall S, Andreotti F, Antman E, Barbato E, Bassand J-P, Bugiardini R, Cikirikcioglu M, Cuisset T, De Bonis M, Delgado V, Fitzsimons D, Gaemperli O, Galiè N, Gilard M, Hamm CW, Ibanez B, Iung B, James S, Knuuti J, Landmesser U, Leclercq C, Lettino M, Lip G, Piepoli MF, Pierard L, Schwerzmann M, Sechtem U, Simpson IA, Uva MS, Stabile E, Storey RF, Tendera M, Van De Werf F, Verheugt F, Aboyans V. 2018. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Journal of Cardio-Thoracic Surgery 53:34–78.
1.
Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann F-J, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL. 2018. Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Revista Española de Cardiología (English Edition) 71:42.
1.
Vaduganathan M, Harrington R, Stone G, Steg G, Gibson C, Hamm C, Price M, Lopes R, Leonardi S, Deliargyris E, Prats J, Mahaffey K, White H, Bhatt D. 2018. Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. EuroIntervention 13:e1841–e1849.
1.
Touboul P-J, Labreuche J, Bruckert E, Schargrodsky H, Prati P, Tosetto A, Hernandez-Hernandez R, Woo K-S, Silva H, Vicaut E, Amarenco P. 2018. Corrigendum to “HDL-C, triglycerides and carotid IMT: A meta-analysis of 21,000 patients with automated edge detection IMT measurement” [Atherosclerosis 232 (2014) 65–71]. Atherosclerosis 273:158.
1.
Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, Cheripelli B, Cho T-H, Fazekas F, Fiehler J, Ford I, Galinovic I, Gellissen S, Golsari A, Gregori J, Günther M, Guibernau J, Häusler KG, Hennerici M, Kemmling A, Marstrand J, Modrau B, Neeb L, Perez De La Ossa N, Puig J, Ringleb P, Roy P, Scheel E, Schonewille W, Serena J, Sunaert S, Villringer K, Wouters A, Thijs V, Ebinger M, Endres M, Fiebach JB, Lemmens R, Muir KW, Nighoghossian N, Pedraza S, Gerloff C. 2018. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset. New England Journal of Medicine 379:611–622.
1.
the GSG, Darlington M, Carbonne B, Mailloux A, Brossard Y, Levy-Mozziconacci A, Cortey A, Maoulida H, Simon T, Rousseau A, Durand-Zaleski I. 2018. Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women. BMC Pregnancy and Childbirth 18:496.
1.
Stone GW, Généreux P, Harrington RA, White HD, Gibson CM, Steg PG, Hamm CW, Mahaffey KW, Price MJ, Prats J, Deliargyris EN, Bhatt DL. 2018. Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial. European Heart Journal 39:4112–4121.
1.
Steg PG, Wijns W. 2018. Towards Drugs and Devices Synergy. A new session track at EuroPCR: PCR clinical algorithms. EuroIntervention 13:1991–1992.
1.
Steg PG, Bhatt DL. 2018. Is There Really a Benefit to Net Clinical Benefit in Testing Antithrombotics? Circulation 137:1429–1431.
1.
Steg PG, Popovic B. 2018. Emergency Coronary Angiography After Out-of-Hospital Cardiac Arrest: Is It Essential or Futile? Circulation: Cardiovascular Interventions 11:e006804.
1.
Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E, Spiro TE, Barnathan ES, Raskob GE. 2018. Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. New England Journal of Medicine 379:1118–1127.
1.
Sorrentino S, Giustino G, Baber U, Sartori S, Cohen DJ, Henry TD, Farhan S, Sharma M, Ariti C, Dangas G, Gibson M, Faggioni M, Krucoff MW, Aquino M, Chandrasekhar J, Moliterno DJ, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. 2018. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). The American Journal of Cardiology 122:1638–1646.
1.
Scirica BM, Mosenzon O, Bhatt DL, Udell JA, Steg PG, McGuire DK, Im K, Kanevsky E, Stahre C, Sjöstrand M, Raz I, Braunwald E. 2018. Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial. JAMA Cardiology 3:155.
1.
Scirica BM, Bansilal S, Davoudi F, Armstrong PW, Clare RM, Schulte PJ, Pieper KS, Becker RC, James SK, Storey RF, Steg PG, Held C, Himmelmann A, Mahaffey KW, Wallentin L, Cannon CP. 2018. Safety of ticagrelor in patients with baseline conduction abnormalities: A PLATO (Study of Platelet Inhibition and Patient Outcomes) analysis. American Heart Journal 202:54–60.
1.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby J-F, Tricoci P, White HD, Zeiher AM. 2018. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine 379:2097–2107.
1.
Roussel R, Steg PG, Mohammedi K, Marre M, Potier L. 2018. Prevention of cardiovascular disease through reduction of glycaemic exposure in type 2 diabetes: A perspective on glucose‐lowering interventions. Diabetes, Obesity and Metabolism 20:238–244.
1.
Picard F, Ducrocq G, Danchin N, Falissard B, Hanon O, Mahe I, Touzé E, Steg PG. 2018. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study. Archives of Cardiovascular Diseases 111:349–356.
1.
Patel JA, Shen L, Hall SM, Benyahia C, Norel X, McAnulty RJ, Moledina S, Silverstein AM, Whittle BJ, Clapp LH. 2018. Prostanoid EP2 Receptors Are Up-Regulated in Human Pulmonary Arterial Hypertension: A Key Anti-Proliferative Target for Treprostinil in Smooth Muscle Cells. International Journal of Molecular Sciences 19:2372.
1.
Olivier CB, Sundaram V, Bhatt DL, Leonardi S, Lopes RD, Ding VY, Yang L, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, White HD, Desai M, Lynch DR, Harrington RA, Mahaffey KW. 2018. Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. International Journal of Cardiology 270:96–101.
1.
Mawhin M-A, Tilly P, Zirka G, Charles A-L, Slimani F, Vonesch J-L, Michel J-B, Bäck M, Norel X, Fabre J-E. 2018. Neutrophils recruited by leukotriene B4 induce features of plaque destabilization during endotoxaemia. Cardiovascular Research 114:1656–1666.
1.
Lindholm D, James SK, Gabrysch K, Storey RF, Himmelmann A, Cannon CP, Mahaffey KW, Steg PG, Held C, Siegbahn A, Wallentin L. 2018. Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study. JAMA Cardiology 3:1160.
1.
Le Bouc R, Clarençon F, Meseguer E, Lapergue B, Consoli A, Turc G, Naggara O, Duong DL, Servan J, Reiner P, Labeyrie MA, Fisselier M, Blanc R, Farhat W, Pires C, Zuber M, Obadia M, Mazighi M, Pico F, Mas J-L, Amarenco P, Samson Y, on behalf of the Paris Stroke C. 2018. Efficacy of Endovascular Therapy in Acute Ischemic Stroke Depends on Age and Clinical Severity. Stroke 49:1686–1694.
1.
Lattuca B, Barber-Chamoux N, Alos B, Sfaxi A, Mulliez A, Miton N, Levasseur T, Servoz C, Derimay F, Hachet O, Motreff P, Metz D, Lairez O, Mewton N, Belle L, Akodad M, Mathivet T, Ecarnot F, Pollet J, Danchin N, Steg P-G, Juillière Y, Bouleti C. 2018. Impact of video on the understanding and satisfaction of patients receiving informed consent before elective inpatient coronary angiography: A randomized trial. American Heart Journal 200:67–74.
1.
Komajda M, Kerneis M, Tavazzi L, Balanescu S, Cosentino F, Cremonesi A, Ferrari R, Kownator S, Szwed H, Mintale I, Olivari Z, Rittger H, Shlyakhto EV, Slapikas R, Steg PG, Valgimigli M, Van Belle E, Tsioufis K, Majda W, Laroche C, Maggioni AP. 2018. The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. European Journal of Preventive Cardiology 25:377–387.
1.
Kerkmeijer LS, Claessen BE, Baber U, Sartori S, Chandrasekhar J, Stefanini GG, Stone GW, Steg PG, Chieffo A, Weisz G, Windecker S, Mikhail GW, Kastrati A, Morice M-C, Dangas GD, De Winter RJ, Mehran R. 2018. Incidence, determinants and clinical impact of definite stent thrombosis on mortality in women: From the WIN-DES collaborative patient-level pooled analysis. International Journal of Cardiology 263:24–28.
1.
Kasner SE, Swaminathan B, Lavados P, Sharma M, Muir K, Veltkamp R, Ameriso SF, Endres M, Lutsep H, Messé SR, Spence JD, Nedeltechev K, Perera K, Santo G, Olavarria V, Lindgren A, Bangdiwala S, Shoamanesh A, Berkowitz SD, Mundl H, Connolly SJ, Hart RG, Abdelhamid N, Abdul Rahman D, Abdul-Saheb M, Abreu P, Abroskina M, Abu Ahmad F, Accassat S, Acciaresi M, Adami A, Ahmad N, Ahmed F, Alberto Hawkes M, Alemseged F, Ali A, Altavilla R, Alwis L, Amarenco P, Amaro S, Amaya Sanchez L, Amelia Pinto A, Ameriso S, Amin H, Amino T, Amjad A, Anagnostou E, Andersen G, Anderson C, Anderson D, Andrea Falco M, Andres Mackinnon F, Andreu D, Androulakis M, Angel Gamero M, Angel Saredo G, Angeles Diaz R, Angels Font M, Anticoli S, Arauz A, Arauz Gongora A, Araya P, Arenillas Lara J, Arias Rivas S, Arnold M, Augustin S, Avelar W, Azevedo E, Babikian V, Bacellar A, Badalyan K, Bae H, Baez Martinez E, Bagelmann H, Bailey P, Bak Z, Baker M, Balazs A, Baldaranov D, Balogun I, Balueva T, Bankuti Z, Bar M, Baranowska A, Bardutzky J, Barker Trejo S, Barlinn J, Baronnet F, Barroso C, Barteys M, Bartolottiova T, Barulin A, Bas M, Bashir S, Basile V, Bathe-Peters R, Bathula R, Batista C, Batur Caglayan H, Baumgartner P, others. 2018. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. The Lancet Neurology 17:1053–1060.
1.
Kaasenbrood L, Bhatt DL, Dorresteijn JAN, Wilson PWF, D’Agostino RB, Massaro JM, Van Der Graaf Y, Cramer MJM, Kappelle LJ, De Borst GJ, Steg PG, Visseren FLJ. 2018. Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART‐REACH Model. Journal of the American Heart Association 7:e009217.
1.
Kalra PR, Greenlaw N, Ford I, Steg PG, Fox KM. 2018. The Reply. The American Journal of Medicine 131:e129.
1.
Joner M, Koppara T, Byrne RA, Castellanos MI, Lewerich J, Novotny J, Guagliumi G, Xhepa E, Adriaenssens T, Godschalk TC, Malik N, Alfonso F, Tada T, Neumann F-J, Desmet W, Ten Berg JM, Gershlick AH, Feldman LJ, Massberg S, Kastrati A. 2018. Neoatherosclerosis in Patients With Coronary Stent Thrombosis. JACC: Cardiovascular Interventions 11:1340–1350.
1.
Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY. 2018. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. New England Journal of Medicine 379:215–225.
1.
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, Caforio ALP, Crea F, Goudevenos JA, Halvorsen S, Hindricks G, Kastrati A, Lenzen MJ, Prescott E, Roffi M, Valgimigli M, Varenhorst C, Vranckx P, Widimský P, Group ESCSD, Collet J-P, Kristensen SD, Aboyans V, Baumbach A, Bugiardini R, Coman IM, Delgado V, Fitzsimons D, Gaemperli O, Gershlick AH, Gielen S, Harjola V-P, Katus HA, Knuuti J, Kolh P, Leclercq C, Lip GYH, Morais J, Neskovic AN, Neumann F-J, Niessner A, Piepoli MF, Richter DJ, Shlyakhto E, Simpson IA, Steg PG, Terkelsen CJ, Thygesen K, Windecker S, Zamorano JL, Zeymer U, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet J-P, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, McDonagh T, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Zamorano JL, Chettibi M, Hayrapetyan HG, Metzler B, Ibrahimov F, Sujayeva V, Beauloye C, Dizdarevic-Hudic L, Karamfiloff K, Skoric B, Antoniades L, Tousek P, Terkelsen PJ, Shaheen SM, Marandi T, Niemelä M, Kedev S, Gilard M, Aladashvili A, Elsaesser A, Kanakakis IG, Merkely B, Gudnason T, others. 2018. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal 39:119–177.
1.
Hoshino T, Sissani L, Labreuche J, Ducrocq G, Lavallée PC, Meseguer E, Guidoux C, Cabrejo L, Hobeanu C, Gongora-Rivera F, Touboul P-J, Steg PG, Amarenco P, for the AI. 2018. Prevalence of Systemic Atherosclerosis Burdens and Overlapping Stroke Etiologies and Their Associations With Long-term Vascular Prognosis in Stroke With Intracranial Atherosclerotic Disease. JAMA Neurology 75:203.
1.
Horowitz JD, De Caterina R, Heresztyn T, Alexander JH, Andersson U, Lopes RD, Steg PG, Hylek EM, Mohan P, Hanna M, Jansky P, Granger CB, Wallentin L. 2018. Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation. Journal of the American College of Cardiology 72:721–733.
1.
Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Wang Y, Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon B-W, Brouns R, Endres M, Muir KW, Bornstein N, Ozturk S, O’Donnell MJ, De Vries Basson MM, Pare G, Pater C, Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ. 2018. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. New England Journal of Medicine 378:2191–2201.
1.
Groves EM, Bhatt DL, Steg PG, Deliargyris EN, Stone GW, Gibson CM, Hamm CW, Mahaffey KW, White HD, Angiolillo DJ, Prats J, Harrington RA, Price MJ, on behalf of the CI. 2018. Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). Circulation: Cardiovascular Interventions 11:e005635.
1.
Grimaldi-Bensouda L, Danchin N, Dallongeville J, Falissard B, Furber A, Cottin Y, Bonello L, Morel O, Leclercq F, Puymirat E, Ghanem F, Delarche N, Benichou J, Abenhaim L. 2018. Effectiveness of new antiplatelets in the prevention of recurrent myocardial infarction. Heart 104:1583–1592.
1.
Golwala HB, Cannon CP, Steg PG, Doros G, Qamar A, Ellis SG, Oldgren J, Ten Berg JM, Kimura T, Hohnloser SH, Lip GYH, Bhatt DL. 2018. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. European Heart Journal 39:1726–1735a.
1.
Gerardin C, Mageau A, Benali K, Jouan F, Ducrocq G, Alexandra J-F, Van Gysel D, Papo T, Sacre K. 2018. Increased FDG-PET/CT pericardial uptake identifies acute pericarditis patients at high risk for relapse. International Journal of Cardiology 271:192–194.
1.
for the SSG, Fraty M, Velho G, Gand E, Fumeron F, Ragot S, Sosner P, Mohammedi K, Gellen B, Saulnier P-J, Halimi J-M, Montaigne D, Ducrocq G, Rehman M, Marre M, Roussel R, Hadjadj S. 2018. Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study. Diabetologia 61:2643–2653.
1.
Faggioni M, Baber U, Afshar AE, Giustino G, Sartori S, Sorrentino S, Steg PG, Stefanini GG, Windecker S, Leon MB, Stone GW, Wijns W, Serruys PW, Valgimigli M, Camenzind E, Weisz G, Smits PC, Kandzari DE, Galatius S, Von Birgelen C, Jeger RV, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim H-S, Kastrati A, Chieffo A, Dangas GD, Morice M-C, Mehran R. 2018. Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions 11:68–76.
1.
El Khoury P, Roussel R, Fumeron F, Abou‐Khalil Y, Velho G, Mohammedi K, Jacob M, Steg PG, Potier L, Ghaleb Y, Elbitar S, Ragot S, Andreata F, Caligiuri G, Hadjadj S, Boileau C, Marre M, Abifadel M, Varret M, Hansel B. 2018. Plasma proprotein‐convertase‐subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes. Diabetes, Obesity and Metabolism 20:943–953.

2017

1.
Westenbrink BD, Alings M, Granger CB, Alexander JH, Lopes RD, Hylek EM, Thomas L, Wojdyla DM, Hanna M, Keltai M, Steg PG, De Caterina R, Wallentin L, Van Gilst WH. 2017. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. American Heart Journal 185:140–149.
1.
Yeh RW, Kereiakes DJ, Steg PG, Cutlip DE, Croce KJ, Massaro JM, Mauri L. 2017. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. Journal of the American College of Cardiology 70:2213–2223.
1.
Welsh RC, Roe MT, Steg PG, James S, Povsic TJ, Bode C, Gibson CM, Ohman EM. 2017. Corrigendum to “A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease” [Am Heart J 181 (2016) 92–100]. American Heart Journal 184:156.
1.
Vidal-Petiot E, Bhatt DL, Fox KM, Steg PG. 2017. Blood pressure and cardiovascular outcomes: a closer look – Authors’ reply. The Lancet 389:1296–1297.
1.
Vidal-Petiot E, Stebbins A, Chiswell K, Ardissino D, Aylward PE, Cannon CP, Ramos Corrales MA, Held C, López-Sendón JL, Stewart RAH, Wallentin L, White HD, Steg PG, on behalf of the SI. 2017. Visit-to-visit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. European Heart Journal 38:2813–2822.
1.
Vedin O, Hagström E, Östlund O, Avezum A, Budaj A, Flather MD, Harrington RA, Koenig W, Soffer J, Siegbahn A, Steg PG, Stewart RAH, Wallentin L, White HD, Held C. 2017. Associations between tooth loss and prognostic biomarkers and the risk for cardiovascular events in patients with stable coronary heart disease. International Journal of Cardiology 245:271–276.
1.
Varshney A, Steg PG, Elbez Y, Sorbets E, Eagle KA, Bhatt DL. 2017. Examining the applicability of SPRINT in patients with subclinical or established atherothrombotic disease: A REACH registry analysis. International Journal of Cardiology 243:95–97.
1.
Vaduganathan M, Harrington RA, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Deliargyris EN, Prats J, Mahaffey KW, White HD, Bhatt DL. 2017. Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). The American Journal of Cardiology 120:1043–1048.
1.
Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson CM, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL, Cura F, Ballarino M, Damonte AA, Grinfeld D, Álvarez CA, Fernandez A, Farshid A, Gunalingam B, Jeurgens C, Lowe H, Hallani H, Nelson G, New G, Dick R, Lefkovits J, Duffy S, Bett N, Yadav R, Garrahy P, Lehman R, Aylward P, Horowitz J, Worthley M, Cross D, Rankin J, Thompson P, Roberts-Thomson P, Cross D, Jayasinghe R, Aroney C, Huber K, Leisch F, Altenberger J, Gaul G, Neunteufl T, Weidinger F, Schuchlenz H, Weber H, Benzer W, Rossi P, Almeida B, Godinho A, Vilas-Boas F, Vacanti L, Serpa R, Jatene JA, Reis G, Saad J, Marino M, Botelho R, Costantini C, Wang R, Precoma D, Rati M, Bodanese L, Manenti E, Zouvi JP, Tumelero R, Herdy A, Filho EM, Carvalho A, Franken R, Title L, Lazzam C, Reeves F, Shaburishvili T, Chapidze G, Mamatsashvili M, Khintibidze I, Heuer H, Olbrich H-G, Genth-Zotz S, Moebius-Winkler S, Buerke M, Hoffmann S, Radke P, Moellmann H, Katus H, Voehringer H-F, Hengstenberg C, Klauss V, Brachmann J, Khan A, Kumar S, Mohanan P, Chandra P, others. 2017. Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. Journal of the American College of Cardiology 69:176–185.
1.
Van Den Berg MJ, Bhatt DL, Kappelle LJ, De Borst GJ, Cramer MJ, Van Der Graaf Y, Steg PG, Visseren FLJ, on behalf of the S study group, investigators RR. 2017. Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria. European Heart Journal 38:3211–3218.
1.
Vaduganathan M, Harrington RA, Stone GW, Deliargyris EN, Steg PG, Gibson CM, Hamm CW, Price MJ, Menozzi A, Prats J, Elkin S, Mahaffey KW, White HD, Bhatt DL. 2017. Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. JAMA Cardiology 2:127.
1.
Vacchina V, Séby F, Chekri R, Verdeil J, Dumont J, Hulin M, Sirot V, Volatier J-L, Serreau R, Rousseau A, Simon T, Guérin T. 2017. Optimization and validation of the methods for the total mercury and methylmercury determination in breast milk. Talanta 167:404–410.
1.
Thomas MR, Angiolillo DJ, Bonaca MP, Ajjan RA, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Sabatine MS, Storey RF. 2017. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. Thrombosis and Haemostasis 117:940–947.
1.
the Papillophar Study G, Lefevre M, Rousseau A, Rayon T, Dalstein V, Clavel C, Beby-Defaux A, Pretet J-L, Soussan P, Polette M, Lacau Saint Guily J, Birembaut P. 2017. Epithelial to mesenchymal transition and HPV infection in squamous cell oropharyngeal carcinomas: the papillophar study. British Journal of Cancer 116:362–369.
1.
Stewart RAH, Held C, Hadziosmanovic N, Armstrong PW, Cannon CP, Granger CB, Hagström E, Hochman JS, Koenig W, Lonn E, Nicolau JC, Steg PG, Vedin O, Wallentin L, White HD. 2017. Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. Journal of the American College of Cardiology 70:1689–1700.
1.
Stewart RAH, Hagström E, Held C, Wang TKM, Armstrong PW, Aylward PE, Cannon CP, Koenig W, López‐Sendón JL, Mohler ER, Hadziosmanovic N, Krug‐Gourley S, Ramos Corrales MA, Siddique S, Steg PG, White HD, Wallentin L, on behalf of the SI. 2017. Self‐Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. Journal of the American Heart Association 6:e006096.
1.
Steinhilber D, Uydeş-Doğan BS, Topal G, Clària J, Norel X, Schebb NH, Bannenberg G. 2017. Editorial—Special issue of the 6th European Workshop on Lipid Mediators. Prostaglandins & Other Lipid Mediators 133:1–3.
1.
Steg PG, Simon T. 2017. Duration of antiplatelet therapy after DES implantation: can we trust non-inferiority open-label trials? European Heart Journal 38:1044–1047.
1.
Steg PG, Harrington RA, Himmelmann A, James SK, Pieper KS, Wallentin L. 2017. Unreliable Observations from a Confounded Analysis of a Skewed Database. The American Journal of Medicine 130:e355–e356.
1.
Sorbets E, Greenlaw N, Ferrari R, Ford I, Fox KM, Tardif J, Tendera M, Steg PG, on behalf of the CI. 2017. Rationale, design, and baseline characteristics of the CLARIFY registry of outpatients with stable coronary artery disease. Clinical Cardiology 40:797–806.
1.
Simon T, Pogu J, Rémy S, Brau F, Pogu S, Maquigneau M, Fonteneau J-F, Poirier N, Vanhove B, Blancho G, Piaggio E, Anegon I, Blancou P. 2017. Inhibition of effector antigen-specific T cells by intradermal administration of heme oxygenase-1 inducers. Journal of Autoimmunity 81:44–55.
1.
Simon T, Danchin N. 2017. Clinical Impact of Pharmacogenomics of Clopidogrel in Stroke. Circulation 135:34–37.
1.
Shah B, Baber U, Pocock SJ, Krucoff MW, Ariti C, Gibson CM, Steg PG, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Iakovou I, Dangas G, Aquino MB, Sartori S, Chieffo A, Moliterno DJ, Colombo A, Mehran R. 2017. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circulation: Cardiovascular Interventions 10:e004981.
1.
Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Steg PG, Massaro JM, Apruzzese PK, Mauri L. 2017. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease. JACC: Cardiovascular Interventions 10:942–954.
1.
Secemsky EA, Yeh RW, Kereiakes DJ, Cutlip DE, Cohen DJ, Steg PG, Cannon CP, Apruzzese PK, D’Agostino RB, Massaro JM, Mauri L, for the Dual Antiplatelet Therapy Study I. 2017. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. JAMA Cardiology 2:478.
1.
Schoos M, Chandrasekhar J, Baber U, Bhasin A, Sartori S, Aquino M, Vogel B, Farhan S, Sorrentino S, Kini A, Kruckoff M, Moliterno D, Henry TD, Weisz G, Gibson CM, Iakovou I, Colombo A, Steg PG, Witzenbichler B, Chieffo A, Cohen D, Stuckey T, Ariti C, Dangas G, Pocock S, Mehran R. 2017. Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). The American Journal of Cardiology 120:904–910.
1.
Sawlani NN, Harrington RA, Stone GW, Steg PG, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris EN, Mahaffey KW, White HD, Bhatt DL. 2017. Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions 10:e004380.
1.
Rouzier R, Uzan C, Rousseau A, Guillot E, Zilberman S, Meyer C, Estevez P, Dupre P-F, Kere D, Doridot V, D’Halluin G, Fritel X, Pouget N, Jankowski C, Mazouni C, Simon T, Coutant C. 2017. Multicenter prospective evaluation of the reliability of the combined use of two models to predict non-sentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: the MSKCC nomogram and the Tenon score. Results of the NOTEGS study. British Journal of Cancer 116:1135–1140.
1.
Rosenzwajg M, Languille E, Debiec H, Hygino J, Dahan K, Simon T, Klatzmann D, Ronco P. 2017. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab. Kidney International 92:227–237.
1.
Roguin A, Camenzind E, Kerner A, Beyar R, Boersma E, Mauri L, Steg PG, Wijns W. 2017. Long-Term Outcomes of Stenting the Proximal Left Anterior Descending Artery in the PROTECT Trial. JACC: Cardiovascular Interventions 10:548–556.
1.
Qaderdan K, Vos G-JA, McAndrew T, Steg PG, Hamm CW, Van‘T Hof A, Mehran R, Deliargyris EN, Bernstein D, Stone GW, Ten Berg JM. 2017. Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials. American Heart Journal 194:73–82.
1.
Puymirat E, Simon T, Cayla G, Cottin Y, Elbaz M, Coste P, Lemesle G, Motreff P, Popovic B, Khalife K, Labèque J-N, Perret T, Le Ray C, Orion L, Jouve B, Blanchard D, Peycher P, Silvain J, Steg PG, Goldstein P, Guéret P, Belle L, Aissaoui N, Ferrières J, Schiele F, Danchin N. 2017. Acute Myocardial Infarction: Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015. Circulation 136:1908–1919.
1.
Puymirat E, Caudron J, Steg PG, Lemesle G, Cottin Y, Coste P, Schiele F, De Labriolle A, Bataille V, Ferrières J, Simon T, Danchin N, for the F-MI investigators. 2017. Prognostic impact of non-compliance with guidelines-recommended times to reperfusion therapy in ST-elevation myocardial infarction. The FAST-MI 2010 registry. European Heart Journal: Acute Cardiovascular Care 6:26–33.
1.
Puymirat E, Aissaoui N, Cayla G, Lafont A, Riant E, Mennuni M, Saint-Jean O, Blanchard D, Jourdain P, Elbaz M, Henry P, Bataille V, Drouet E, Mulak G, Schiele F, Ferrières J, Simon T, Danchin N. 2017. Changes in One-Year Mortality in Elderly Patients Admitted with Acute Myocardial Infarction in Relation with Early Management. The American Journal of Medicine 130:555–563.
1.
Puymirat E, Aissaoui N, Lemesle G, Cottin Y, Coste P, Schiele F, Ferrières J, Simon T, Danchin N. 2017. Long-Term Clinical Outcomes According to Previous Manifestations of Atherosclerotic Disease (from the FAST-MI 2010 Registry). The American Journal of Cardiology 119:692–697.
1.
Potier L, Roussel R, Elbez Y, Marre M, Zeymer U, Reid CM, Ohman M, Eagle KA, Bhatt DL, Steg PG. 2017. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart 103:1339–1346.
1.
Pollack CV, Davoudi F, Diercks DB, Becker RC, James SK, Lim ST, Schulte PJ, Spinar J, Steg PG, Storey RF, Himmelmann A, Wallentin L, Cannon CP, on behalf of the PI. 2017. Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non–ST‐segment elevation acute coronary syndrome in the PLATO trial. Clinical Cardiology 40:390–398.
1.
Parma Z, Steg PG, Greenlaw N, Ferrari R, Ford I, Fox K, Tardif J-C, Morais J, Gamba MA, Kääb S, Tendera For The Clarify Investigators M. 2017. Differences in outcomes in patients with stable coronary artery disease managed by cardiologists versus non-cardiologists: the international prospective CLARIFY registry. Polish Archives of Internal Medicine https://doi.org/10.20452/pamw.3902.
1.
Parker WA, Bhatt DL, Prats J, Day JRS, Steg PG, Stone GW, Hamm CW, Mahaffey KW, Price MJ, Michael Gibson C, White HD, Storey RF, the CPI. 2017. Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thrombosis and Haemostasis 117:1093–1100.
1.
Palmerini T, Bacchi Reggiani L, Della Riva D, Romanello M, Feres F, Abizaid A, Gilard M, Morice M-C, Valgimigli M, Hong M-K, Kim B-K, Jang Y, Kim H-S, Park KW, Colombo A, Chieffo A, Ahn J-M, Park S-J, Schüpke S, Kastrati A, Montalescot G, Steg PG, Diallo A, Vicaut E, Helft G, Biondi-Zoccai G, Xu B, Han Y, Genereux P, Bhatt DL, Stone GW. 2017. Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. Journal of the American College of Cardiology 69:2011–2022.
1.
Ozen G, Norel X. 2017. Prostanoids in the pathophysiology of human coronary artery. Prostaglandins & Other Lipid Mediators 133:20–28.
1.
Ozen G, Gomez I, Daci A, Deschildre C, Boubaya L, Teskin O, Uydeş‐Doğan BS, Jakobsson P, Longrois D, Topal G, Norel X. 2017. I nhibition of microsomal PGE synthase‐1 reduces human vascular tone by increasing PGI2 : a safer alternative to COX‐2 inhibition. British Journal of Pharmacology 174:4087–4098.
1.
On behalf of the PI, Lowenstern A, Storey RF, Neely M, Sun J-L, Angiolillo DJ, Cannon CP, Himmelmann A, Huber K, James SK, Katus HA, Morais J, Siegbahn A, Steg PG, Wallentin L, Becker RC. 2017. Platelet-related biomarkers and their response to inhibition with aspirin and p2y12-receptor antagonists in patients with acute coronary syndrome. Journal of Thrombosis and Thrombolysis 44:145–153.
1.
Ohman EM, Roe MT, Steg PG, James SK, Povsic TJ, White J, Rockhold F, Plotnikov A, Mundl H, Strony J, Sun X, Husted S, Tendera M, Montalescot G, Bahit MC, Ardissino D, Bueno H, Claeys MJ, Nicolau JC, Cornel JH, Goto S, Kiss RG, Güray Ü, Park D-W, Bode C, Welsh RC, Gibson CM. 2017. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. The Lancet 389:1799–1808.
1.
O’Donnell-Luria AH, Lin AP, Merugumala SK, Rohr F, Waisbren SE, Lynch R, Tchekmedyian V, Goldberg AD, Bellinger A, McFaline-Figueroa JR, Simon T, Gershanik EF, Levy BD, Cohen DE, Samuels MA, Berry GT, Frank NY. 2017. Brain MRS glutamine as a biomarker to guide therapy of hyperammonemic coma. Molecular Genetics and Metabolism 121:9–15.
1.
Mas J-L, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, Arquizan C, Béjot Y, Vuillier F, Detante O, Guidoux C, Canaple S, Vaduva C, Dequatre-Ponchelle N, Sibon I, Garnier P, Ferrier A, Timsit S, Robinet-Borgomano E, Sablot D, Lacour J-C, Zuber M, Favrole P, Pinel J-F, Apoil M, Reiner P, Lefebvre C, Guérin P, Piot C, Rossi R, Dubois-Randé J-L, Eicher J-C, Meneveau N, Lusson J-R, Bertrand B, Schleich J-M, Godart F, Thambo J-B, Leborgne L, Michel P, Pierard L, Turc G, Barthelet M, Charles-Nelson A, Weimar C, Moulin T, Juliard J-M, Chatellier G. 2017. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. New England Journal of Medicine 377:1011–1021.
1.
McCarthy CP, Steg G, Bhatt DL. 2017. The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum. European Heart Journal 38:3488–3492.